prednisone and Proteinuria studies

Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.

Proteinuria: The presence of proteins in the urine, an indicator of KIDNEY DISEASES.

Research Excerpts

Excerpt	Relevance	Reference
"A prospective, multi-center, randomized controlled study was conducted to evaluate the efficacy and safety of a 24-week course low-dose leflunomide combined with prednisone in the induction treatment of proliferative lupus nephritis in Chinese patients."	9.30	Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial. ( Chen, J; Chen, Q; Guan, T; Jiang, G; Li, D; Luo, P; Ni, Z; Qi, C; Sun, M; Sun, Z; Wan, J; Wang, L; Wang, S; Xing, C; Zha, Y; Zhang, M, 2019)
" Importantly, furosemide treatment did not further increase the expression of Kim-1 and NGAL in HK-2 cells upregulated by massive proteinuria."	9.27	Massive Proteinuria-Induced Injury of Tubular Epithelial Cells in Nephrotic Syndrome is Not Exacerbated by Furosemide. ( Jing, KP; Li, JJ; Liu, HF; Liu, WJ; Pan, Q; Tang, HX; Wang, S; Wu, HL; Xu, C; Ye, L; Zou, T, 2018)
"The addition of prednisone after mizoribine monotherapy can be beneficial for all IMN patients with nephrotic-range proteinuria syndrome."	9.17	Efficacy of mizoribine followed by low-dose prednisone in patients with idiopathic membranous nephropathy and nephrotic-range proteinuria. ( Matsumoto, Y; Moriki, T; Nojima, Y; Shimada, Y, 2013)
"Intravenous cyclophosphamide with prednisone is an effective treatment for lupus nephritis, but with significant toxicities."	9.15	Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial. ( Chen, J; Chen, W; Fan, A; Fu, J; Fu, P; Kong, Y; Li, Z; Liao, Y; Liu, F; Liu, Q; Liu, Z; Lou, T; Rao, S; Tang, X; Yang, Z; Yu, X; Zhang, J, 2011)
" However, the efficacy and safety of combined therapy of low-dose tacrolimus and prednisone in the treatment of nephrotic syndrome (NS) with slight mesangial proliferation has not been reported."	9.12	Combined therapy of low-dose tacrolimus and prednisone in nephrotic syndrome with slight mesangial proliferation. ( Jia, Y; Miao, L; Sun, J; Xu, Z; Yuan, H, 2006)
"The aim of study was the analysis of cyclosporine A (CyA) treatment efficacy in children with steroid-dependent nephrotic syndrome (NS)."	9.11	[The effect of cyclosporine A in steroid-dependent nephrotic syndrome in children]. ( Tenderenda, E; Tomaszewska, B; Wasilewska, A; Zoch-Zwierz, W, 2005)
"Thirty-eight patients with diffuse glomerulonephritis of systemic lupus erythematosus were randomly assigned to add cyclophosphamide, azathioprine, or nothing to low-dose corticosteroid treatment and have been followed for a mean of 21/3 years thereafter."	9.04	Cyclophosphamide or azathioprine in lupus glomerulonephritis. A controlled trial: results at 28 months. ( Decker, JL; Klippel, JH; Plotz, PH; Steinberg, AD, 1975)
"The proteinuria selectivity index (PSI) can predict the response to prednisone in the primary nephrotic syndrome (PNS)."	7.96	Proteinuria selectivity and prednisone response in children with nephrotic syndrome. ( Ochoa-Ponce, C; Ornelas-Álvarez, VM; Pérez-Cortés, G; Pérez-Molina, JJ; Ramírez-Godínez, S, 2020)
"To investigate the effects of prednisone on the expressions of FAK and Pyk2 in the kidneys of rats with adriamycin-induced nephritis."	7.80	[Effects of prednisone on renal FAK and Pyk2 expressions in rats with adriamycin- induced nephritis]. ( Chen, X; Lin, X; Liu, C; Wang, J; Wu, X; Zheng, J, 2014)
" The objective of this study was to limit nuclear factor κB (NF-κB) activation which is up-regulated in these patients, aiming at decreasing proteinuria and prednisone need."	7.78	Saquinavir in steroid-dependent and -resistant nephrotic syndrome: a pilot study. ( Amore, A; Camilla, R; Coppo, R; Dal Canton, A; Daprà, V; Esposito, C; Esposito, P; Fonsato, V; Gianoglio, B; Loiacono, E; Peruzzi, L; Porcellini, MG; Tovo, PA, 2012)
"Tacrolimus showed a rapid proteinuria remission in refractory IgAN patients."	7.78	Tacrolimus improves the proteinuria remission in patients with refractory IgA nephropathy. ( Chen, YQ; Liu, LJ; Lv, JC; Shi, SF; Wang, HY; Zhang, H; Zhang, Q; Zhu, L, 2012)
"To evaluate the efficacy of pentoxifylline in the treatment of refractory nephrotic syndrome secondary to lupus nephritis."	7.72	Pentoxifylline in the treatment of refractory nephrotic syndrome secondary to lupus nephritis. ( Aviña-Zubieta, JA; Bustamante, R; Esquivel-Nava, G; Galindo-Rodríguez, G; Salazar-Exaire, D; Vadillo-Buenfil, M; Vela-Ojeda, J, 2003)
"Despite significant effects of melphalan and prednisone in the therapy of systemic AL-amyloidosis, overall prognosis is poor and remission of clinical symptoms cannot generally be expected."	7.70	[Systemic Al-amyloidosis. Clinical course and limits of melphalan therapy]. ( Grabensee, B; Heering, P; Hetzel, GR, 1999)
"Six children with steroid-resistant nephrotic syndrome (SRNS) and one patient affected by Alport syndrome and nephrotic-range proteinuria received enalapril (mean dose 0."	7.70	Enalapril: antiproteinuric effect in children with nephrotic syndrome. ( Lama, G; Luongo, I; Piscitelli, A; Salsano, ME, 2000)
"The effect of enalapril and low prednisone doses on the urinary protein electrophoretic pattern was studied in 13 pediatric patients with glomerular diseases and steroid-resistant nephrotic syndrome."	7.70	Enalapril and prednisone in children with nephrotic-range proteinuria. ( Cano, F; Cumsille, MA; Delucchi, A; Gonzalez, X; Rodriguez, E; Wolff, E, 2000)
"Prednisone improves serum creatinine and proteinuria in a substantial proportion of adults with HIV-AN."	7.69	Prednisone improves renal function and proteinuria in human immunodeficiency virus-associated nephropathy. ( Austen, JL; Carey, JT; Emancipator, SN; Gripshover, B; Herbener, T; Kalayjian, RC; Mbanefo, C; Phinney, M; Rahman, M; Salata, RA; Smith, MC; Weigel, K, 1996)
"A multi-centre controlled trial of prednisone in the nephrotic syndrome in adults was run by the Medical Research Council between 1962 and 1966."	7.68	Glomerular tip lesion in the 1962-66 Medical Research Council trial of prednisone in the nephrotic syndrome. ( Howie, AJ; Kizaki, T, 1993)
"Treatment of patients with membranous glomerulonephritis with prednisone on alternate days results in a decreased proteinuria on non-prednisone days."	7.68	Decreases of proteinuria during alternate-day prednisone therapy in nephrotic syndrome. ( Hoitsma, AJ; Koene, RA; Wetzels, JF, 1990)
" The heavy proteinuria exhibited a striking steroid-dependent course during a three-year period of time, with ten relapses occurring whenever attempts were made to withdraw prednisone therapy."	7.67	Steroid-dependent nephrotic syndrome in lupus nephritis. Response to chlorambucil. ( Abuelo, JG; Esparza, AR; Garella, S, 1984)
"We studied the effect of prednisone on urinary protein excretion in 19 patients with a nephrotic syndrome, who were treated with prednisone (125-150 mg) on alternate days."	7.67	Prednisone-induced fluctuations of proteinuria in patients with a nephrotic syndrome. ( Gerlag, PG; Hoitsma, AJ; Koene, RA; Sluiter, HE; Wetzels, JF, 1986)
"Thirteen adult patients with nephrotic syndrome resistant to corticosteroid administration were treated with azathioprine daily for four years."	7.67	Effect of long-term azathioprine administration in adults with minimal-change glomerulonephritis and nephrotic syndrome resistant to corticosteroids. ( Cade, R; Campbell, K; Croker, B; Mars, D; Peterson, J; Privette, M; Thompson, R, 1986)
"Administration of prednisone to patients with nephrotic syndromes of different aetiologies caused an abrupt increase of proteinuria."	7.66	Prednisone-induced increase of proteinuria in patients with a nephrotic syndrome. ( Gerlag, PG; Koene, RA; van Liebergen, FJ, 1983)
"Seven patients with slight but definite proliferative changes in the glomeruli achieved complete remission of the nephrotic syndrome when treated with prednisone."	7.66	Nephrotic syndrome with slight proliferative changes in the glomeruli: response to prednisone. ( Ezedum, S; Kerr, DN; Morley, AR; Rashid, H, 1980)
"In this paper, the effect of the administration of prednisone and azathioprine on an experimental immune complex glomerulonephritis is studied."	7.65	Experimental glomerulonephritis in the rat induced by antibodies directed against tubular antigens. II. Influence of medication with prednisone and azathioprine: a histologic and immunohistologic study at the light microscopic and the ultrastructural leve ( Arends, A; Feenstra, K; Greben, HA; Hoedemaeker, PJ; van den Lee, R, 1975)
" The main adverse effects in TAC treatment were glucose intolerance, diabetes and abnormal aminotransferase."	6.84	The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy. ( Chen, J; Li, H; Li, X; Liang, Q; Qu, F; Xie, X, 2017)
"Tacrolimus has been used for idiopathic membranous nephropathy (IMN) therapy, but most patients who achieved remission showed a high relapse rate when tacrolimus was withdrawn after 6-12 months of therapy."	6.78	Effect of prolonged tacrolimus treatment in idiopathic membranous nephropathy with nephrotic syndrome. ( Jia, Y; Liu, N; Luo, P; Miao, LN; Sun, GD; Yuan, H, 2013)
"For patients with diffuse proliferative lupus nephritis, azathioprine or cyclosporine combined with corticosteroids demonstrated equal efficacy in the prevention of flares."	6.72	A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. ( Alberighi, OD; Altieri, P; Doria, A; Ferraccioli, G; Ferrara, R; Greco, S; Manno, C; Moroni, G; Mosca, M; Ponticelli, C; Todesco, S, 2006)
" Beginning from the second LDL-A course, a dosage of 1 mg/kg/d of prednisone was administered for 6 weeks, then tapered."	6.71	A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children. ( Akioka, Y; Chikamoto, H; Fukazawa, A; Hattori, M; Ito, K; Kawaguchi, H; Khono, M; Matsunaga, A; Miyakawa, S; Nakakura, H; Ogino, D, 2003)
"Treatment with indomethacin, aspirin, or prednisone has been shown to reduce urinary fibrin/fibrinogen degradation products (F."	6.64	Modification by drugs of urinary fibrin/fibrinogen degradation products in glomerulonephritis. ( Cash, JD; Clarkson, AR; MacDonald, MK; Robson, JS, 1972)
" The aim of this study was to investigate the efficacy and safety of bortezomib combined with glucocorticoids in refractory lupus patients."	5.46	The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis. ( Hou, J; Hu, W; Huang, L; Huang, X; Liu, Z; Zhang, H; Zhou, M, 2017)
"Proteinuria was 2."	5.38	The dynamics of urinary N-acetyl-β-D-glucosaminidase (NAG), a marker of renal tubular dysfunction, in patients with lupus nephritis undergoing oral prednisone therapy. ( Bob, F; Bozdog, G; Cioca, D; Gadalean, F; Gluhovschi, C; Gluhovschi, G; Kaycsa, A; Marian, R; Petrica, L; Velciov, S; Vernic, C, 2012)
"The treatment of membranous lupus nephritis (MLN) is still controversial in the literature."	5.37	Prednisone monotherapy induced remission in a group of patients with membranous lupus nephritis. ( Alves de Brito, G; Bitencourt Dias, C; Dos Santos Silva, V; Gera Abrão, J; Malafronte, P; Pinheiro, CC; Titan, S; Toledo Barros, R; Woronik, V, 2011)
"A prospective, multi-center, randomized controlled study was conducted to evaluate the efficacy and safety of a 24-week course low-dose leflunomide combined with prednisone in the induction treatment of proliferative lupus nephritis in Chinese patients."	5.30	Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial. ( Chen, J; Chen, Q; Guan, T; Jiang, G; Li, D; Luo, P; Ni, Z; Qi, C; Sun, M; Sun, Z; Wan, J; Wang, L; Wang, S; Xing, C; Zha, Y; Zhang, M, 2019)
" Importantly, furosemide treatment did not further increase the expression of Kim-1 and NGAL in HK-2 cells upregulated by massive proteinuria."	5.27	Massive Proteinuria-Induced Injury of Tubular Epithelial Cells in Nephrotic Syndrome is Not Exacerbated by Furosemide. ( Jing, KP; Li, JJ; Liu, HF; Liu, WJ; Pan, Q; Tang, HX; Wang, S; Wu, HL; Xu, C; Ye, L; Zou, T, 2018)
"MMF plus prednisone versus full-dose prednisone did not differ in reducing proteinuria, but patients treated with the former had fewer adverse events in patients with IgAN with active proliferative lesions."	5.24	Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial. ( Chen, JH; Chen, N; Fu, P; Hou, JH; Hu, ZX; Le, WB; Liang, SS; Liu, D; Liu, ZH; Liu, ZS; Tian, J; Wang, WM; Zeng, CH; Zhang, HT; Zhou, ML, 2017)
"The addition of prednisone after mizoribine monotherapy can be beneficial for all IMN patients with nephrotic-range proteinuria syndrome."	5.17	Efficacy of mizoribine followed by low-dose prednisone in patients with idiopathic membranous nephropathy and nephrotic-range proteinuria. ( Matsumoto, Y; Moriki, T; Nojima, Y; Shimada, Y, 2013)
"Intravenous cyclophosphamide with prednisone is an effective treatment for lupus nephritis, but with significant toxicities."	5.15	Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial. ( Chen, J; Chen, W; Fan, A; Fu, J; Fu, P; Kong, Y; Li, Z; Liao, Y; Liu, F; Liu, Q; Liu, Z; Lou, T; Rao, S; Tang, X; Yang, Z; Yu, X; Zhang, J, 2011)
" In the multivariate analysis, baseline serum creatinine and 24-h proteinuria were independent predictors of the risk of primary outcome; treatment with prednisone plus ramipril significantly reduced the risk of renal disease progression (hazard ratio 0."	5.14	Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. ( Manno, C; Pesce, F; Rossini, M; Schena, FP; Torres, DD, 2009)
"This observational study aimed to evaluate the results of treatment with low-dose chlorambucil in combination with corticosteroids in patients with idiopathic membranous nephropathy (iMGN) and nephrotic syndrome."	5.14	Efficacy and safety of low-dose chlorambucil in nephrotic patients with idiopathic membranous nephropathy. ( Idasiak-Piechocka, I; Oko, A; Skrobańska, B; Łochyńska-Bielecka, K, 2009)
" However, the efficacy and safety of combined therapy of low-dose tacrolimus and prednisone in the treatment of nephrotic syndrome (NS) with slight mesangial proliferation has not been reported."	5.12	Combined therapy of low-dose tacrolimus and prednisone in nephrotic syndrome with slight mesangial proliferation. ( Jia, Y; Miao, L; Sun, J; Xu, Z; Yuan, H, 2006)
"The aim of study was the analysis of cyclosporine A (CyA) treatment efficacy in children with steroid-dependent nephrotic syndrome (NS)."	5.11	[The effect of cyclosporine A in steroid-dependent nephrotic syndrome in children]. ( Tenderenda, E; Tomaszewska, B; Wasilewska, A; Zoch-Zwierz, W, 2005)
"The effects of a combined schedule of prednisone and cyclophosphamide was analysed in the specific subset of IgA nephropathy patients with acute inflammatory histologic changes associated with haematuria and proteinuria."	5.09	Steroid and cyclophosphamide in IgA nephropathy. ( Berutti, S; Cesano, G; Ferro, M; Piccoli, G; Roccatello, D; Rossi, D; Salomone, M; Sena, LM, 2000)
"We conducted a randomized trial in 51 biopsy-proven idiopathic MGN patients with nephrotic-range proteinuria comparing 26 weeks of cyclosporine treatment plus low-dose prednisone to placebo plus prednisone."	5.09	Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. ( Appel, GB; Cattran, DC; Hebert, LA; Hoy, WE; Hunsicker, LG; Kunis, CL; Maxwell, DR; Pohl, MA, 2001)
" Long term alternate-day prednisone treatment according the protocol of Waldo allows to decrease haematuria and proteinuria in children with IgAN and HSN 2."	5.09	[Evaluation of prednisone treatment in children with IgA nephropathy and Schönlein-Henoch nephropathy according to the Waldo protocol with regard to pathomorphologic changes in renal biopsy]. ( Mizerska-Wasiak, M; Roszkowska-Blaim, M; Szymanik-Grzelak, H, 2001)
" The following indirect parameters of reactive oxygen species activity were determined in nephrotic patients during four stages of the disease (full relapse before prednisone administration, disappearance of proteinuria, prednisone cessation, unmaintained remission): plasma malondialdehyde (MDA) levels, copper/zinc superoxide dismutase (CuZn SOD) activity and glutathione peroxidase (GPX) activity in erythrocytes, reduced glutathione (GSH) and vitamin C levels in whole blood, and vitamin E level in serum."	5.08	Antioxidant status of children with steroid-sensitive nephrotic syndrome. ( Brodkiewicz, A; Bukowska, H; Fydryk, J; Gonet, B; Jacobson, E; Kurzawska, O; Małecka, G; Urasiński, T, 1998)
" It was found that RTX did not significantly improve serum albumin levels and e-GFR when compared with the control group (including cyclosporine and cyclophosphamide, chlorambucil, prednisone, non-immunosuppressive anti-proteinuria treatment), serum albumin levels (OR = 0."	5.05	Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis. ( Gong, S; Li, J; Lu, W; Luo, H; Wang, Y, 2020)
"Thirty-eight patients with diffuse glomerulonephritis of systemic lupus erythematosus were randomly assigned to add cyclophosphamide, azathioprine, or nothing to low-dose corticosteroid treatment and have been followed for a mean of 21/3 years thereafter."	5.04	Cyclophosphamide or azathioprine in lupus glomerulonephritis. A controlled trial: results at 28 months. ( Decker, JL; Klippel, JH; Plotz, PH; Steinberg, AD, 1975)
"Patients with various forms of glomerulonephritis, but excluding those with minimal glomerular changes, were admitted to a controlled trial of a regimen which combined azathioprine in a dosage of 2."	5.03	Controlled trial of azathioprine and prednisone in chronic renal disease. Report by Medical Research Council Working Party. ( , 1971)
"In patient who develops ibandronate-associated CFSGS, proteinuria appears to be at least partially reversible with the treatment of prednisone and/or tacrolimus if the syndrome is recognized early and ibandronate is stopped."	4.91	Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature. ( Cormack, FC; Gralow, JR; Jia, N; Najafian, B; Shiue, Z; Xie, B, 2015)
"Normally, Kimura disease-associated nephrotic syndrome patients are sensitive to prednisone therapy but are likely to relapse."	4.85	Kimura disease: a case report and review of the Chinese literature. ( Chen, YF; Gu, WZ; Liu, AM; Mao, JH; Wang, DY; Zhang, Y; Zhao, SA, 2009)
" Pioglitazone, a PPAR-γ agonist with a protective action on podocytes, was reported in a few cases as helpful in reducing proteinuria when combined with steroids."	4.84	Pioglitazone, a PPAR-y agonist, as one of the new therapeutic candidates for C3 glomerulopathy. ( Balestra, E; Barbi, E; Ceconi, V; Conversano, E; Di Maso, V; Pennesi, M, 2024)
"Prednisone monotherapy is the treatment of choice for patients with a nephrotic syndrome due to minimal change glomerulopathy."	4.80	[Immunosuppressive treatment of patients with a nephrotic syndrome due to minimal change glomerulopathy]. ( Branten, AJ; Wetzels, JF, 1998)
"This study aims to explore the nephrotoxicity due to use of combination of cyclosporine A and hormone in the treatment of nephrotic syndrome."	4.02	Clinical nephrotoxicity induced by cyclosporin A combined with hormone therapy for nephrotic syndrome. ( Huang, Y; Li, G; Liu, X; Song, Q; Wang, C; Wang, R; Xun, Z, 2021)
"Serious renal pathological changes, mass proteinuria, higher SLEDAI, higher prednisone dose, and a decline in CD4+ T cells could be risk factors for CM in patients with LN."	3.96	Cryptococcal meningitis in patients with lupus nephritis. ( Chen, J; Chen, P, 2020)
"The proteinuria selectivity index (PSI) can predict the response to prednisone in the primary nephrotic syndrome (PNS)."	3.96	Proteinuria selectivity and prednisone response in children with nephrotic syndrome. ( Ochoa-Ponce, C; Ornelas-Álvarez, VM; Pérez-Cortés, G; Pérez-Molina, JJ; Ramírez-Godínez, S, 2020)
" We analyzed the rates of remission (defined on the basis of the Birmingham Vasculitis Activity Score [BVAS]) and relapse as well as the variations over time in estimated glomerular filtration rate (GFR), proteinuria, C-reactive protein (CRP) level, BVAS, and prednisone dose."	3.88	Brief Report: Rituximab for the Treatment of Adult-Onset IgA Vasculitis (Henoch-Schönlein). ( Emmi, G; Eriksson, P; Fenoglio, R; Goldoni, M; Harris, H; Incerti, M; Jayne, D; Maritati, F; Mohammad, AJ; Nicastro, M; Novikov, P; Pillebout, E; Roccatello, D; Rocco, R; Segelmark, M; Silvestri, E; Trivioli, G; Urban, ML; Vaglio, A, 2018)
" Under treatment with oral prednisone mean eGFR significantly improved from 38 ± 21 ml/min to 57 ± 26 ml/min and proteinuria decreased from 981 ± 304 mg/24 hrs to 176 ± 77 mg/24 hrs at the end of follow-up."	3.81	Renal sarcoidosis: epidemiological and follow-up data in a cohort of 27 patients. ( Bergner, R; Löffler, C; Löffler, U; Tuleweit, A; Uppenkamp, M; Waldherr, R, 2015)
"Prednisone treatment dose-dependently attenuated the lupus symptoms in MRL/lpr mice with decreased proteinuria levels, prolonged survival times, decreased serum anti-nuclear antibody levels, and reduced spleen and thymus indices."	3.81	Prednisone treatment inhibits the differentiation of B lymphocytes into plasma cells in MRL/MpSlac-lpr mice. ( Deng, XM; Sun, XJ; Wang, QT; Wei, W; Yan, SX, 2015)
"To investigate the effects of prednisone on the expressions of FAK and Pyk2 in the kidneys of rats with adriamycin-induced nephritis."	3.80	[Effects of prednisone on renal FAK and Pyk2 expressions in rats with adriamycin- induced nephritis]. ( Chen, X; Lin, X; Liu, C; Wang, J; Wu, X; Zheng, J, 2014)
"Prednisone is a mainstay of treatment for patients with focal segmental glomerulosclerosis (FSGS), a disease characterized by reduced podocyte number and glomerulosclerosis."	3.79	Podocyte repopulation by renal progenitor cells following glucocorticoids treatment in experimental FSGS. ( Krofft, RD; Liu, ZH; Naito, S; Pippin, JW; Shankland, SJ; Zhang, J, 2013)
"9 g 24-h proteinuria while still in remission of the protein-losing enteropathy, receiving 5 mg prednisone and 100 mg azathioprine daily."	3.78	Protein-losing enteropathy as initial manifestation of systemic lupus erythematosus. ( Braga, LL; Brandão, LA; Carneiro, FO; Rocha, FA; Sampaio, LR, 2012)
" The objective of this study was to limit nuclear factor κB (NF-κB) activation which is up-regulated in these patients, aiming at decreasing proteinuria and prednisone need."	3.78	Saquinavir in steroid-dependent and -resistant nephrotic syndrome: a pilot study. ( Amore, A; Camilla, R; Coppo, R; Dal Canton, A; Daprà, V; Esposito, C; Esposito, P; Fonsato, V; Gianoglio, B; Loiacono, E; Peruzzi, L; Porcellini, MG; Tovo, PA, 2012)
"Tacrolimus showed a rapid proteinuria remission in refractory IgAN patients."	3.78	Tacrolimus improves the proteinuria remission in patients with refractory IgA nephropathy. ( Chen, YQ; Liu, LJ; Lv, JC; Shi, SF; Wang, HY; Zhang, H; Zhang, Q; Zhu, L, 2012)
" Patients with isolated hematuria and/or proteinuria <50 mg/kg/day received triptolide alone, and those with nephrotic range proteinuria received a combination therapy of prednisone and triptolide."	3.77	Clinical outcomes in children with Henoch-Schönlein purpura nephritis grade IIIa or IIIb. ( Cao, L; Chen, Y; Du, L; Fu, H; Liu, A; Mao, J; Wang, D; Xia, Y; Yao, S, 2011)
"The authors would like to underline the very rare coincidence of Hodgkin's disease and nephrotic syndrome, the lack of remission after routine prednisone administration and disappearance of nephrotic proteinuria after anticancer therapy."	3.74	Hodgkin's disease--the rare cause of nephrotic syndrome in children. ( Brodkiewicz, A; Peregud-Pogorzelski, J; Szychot, E; Zakowska, A, 2008)
"Nephrin, podocin, CD2AP, and alpha-actinin-4 are important podocyte proteins that help maintain the integrity of the slit diaphragm and prevent proteinuria."	3.73	Diversities of podocyte molecular changes induced by different antiproteinuria drugs. ( Ding, J; Fan, Q; Guan, N; Xing, Y, 2006)
"To evaluate the efficacy of pentoxifylline in the treatment of refractory nephrotic syndrome secondary to lupus nephritis."	3.72	Pentoxifylline in the treatment of refractory nephrotic syndrome secondary to lupus nephritis. ( Aviña-Zubieta, JA; Bustamante, R; Esquivel-Nava, G; Galindo-Rodríguez, G; Salazar-Exaire, D; Vadillo-Buenfil, M; Vela-Ojeda, J, 2003)
"Despite significant effects of melphalan and prednisone in the therapy of systemic AL-amyloidosis, overall prognosis is poor and remission of clinical symptoms cannot generally be expected."	3.70	[Systemic Al-amyloidosis. Clinical course and limits of melphalan therapy]. ( Grabensee, B; Heering, P; Hetzel, GR, 1999)
"Seven lupus nephritis patients who failed to respond to at least prednisone and cyclophosphamide were studied."	3.70	Intravenous immunoglobulin treatment of lupus nephritis. ( Fabbrizzi, F; George, J; Langevitz, P; Levy, Y; Lukac, J; Poprac, P; Rauova, L; Rovensky, J; Sherer, Y; Shoenfeld, Y, 2000)
"Six children with steroid-resistant nephrotic syndrome (SRNS) and one patient affected by Alport syndrome and nephrotic-range proteinuria received enalapril (mean dose 0."	3.70	Enalapril: antiproteinuric effect in children with nephrotic syndrome. ( Lama, G; Luongo, I; Piscitelli, A; Salsano, ME, 2000)
"The effect of enalapril and low prednisone doses on the urinary protein electrophoretic pattern was studied in 13 pediatric patients with glomerular diseases and steroid-resistant nephrotic syndrome."	3.70	Enalapril and prednisone in children with nephrotic-range proteinuria. ( Cano, F; Cumsille, MA; Delucchi, A; Gonzalez, X; Rodriguez, E; Wolff, E, 2000)
"Prednisone improves serum creatinine and proteinuria in a substantial proportion of adults with HIV-AN."	3.69	Prednisone improves renal function and proteinuria in human immunodeficiency virus-associated nephropathy. ( Austen, JL; Carey, JT; Emancipator, SN; Gripshover, B; Herbener, T; Kalayjian, RC; Mbanefo, C; Phinney, M; Rahman, M; Salata, RA; Smith, MC; Weigel, K, 1996)
"A multi-centre controlled trial of prednisone in the nephrotic syndrome in adults was run by the Medical Research Council between 1962 and 1966."	3.68	Glomerular tip lesion in the 1962-66 Medical Research Council trial of prednisone in the nephrotic syndrome. ( Howie, AJ; Kizaki, T, 1993)
" The heavy proteinuria exhibited a striking steroid-dependent course during a three-year period of time, with ten relapses occurring whenever attempts were made to withdraw prednisone therapy."	3.67	Steroid-dependent nephrotic syndrome in lupus nephritis. Response to chlorambucil. ( Abuelo, JG; Esparza, AR; Garella, S, 1984)
"By univariate analysis of patients with membraneous nephropathy, terminal renal failure was associated with male sex, a large amount of proteinuria, low serum albumin concentration, low creatinine clearance rate, high serum creatinine concentration, and high systolic blood pressure, but was not associated with age or prednisone treatment."	3.67	Membranous nephropathy: predictors of terminal renal failure. ( Biava, CG; Hopper, J; Petitti, DB; Tu, WH; Tulunay, O, 1984)
"We studied the effects of cyclosporin A (CsA), given for three months, in 14 patients with nephrotic syndrome refractory to treatment with prednisone and/or other immunosuppressants."	3.67	Contrasting response to cyclosporin in refractory nephrotic syndrome. ( Kramer, P; Mulder, P; Schalekamp, MA; Weimar, W; Wenting, GJ; Zietse, R, 1989)
"Thirteen adult patients with nephrotic syndrome resistant to corticosteroid administration were treated with azathioprine daily for four years."	3.67	Effect of long-term azathioprine administration in adults with minimal-change glomerulonephritis and nephrotic syndrome resistant to corticosteroids. ( Cade, R; Campbell, K; Croker, B; Mars, D; Peterson, J; Privette, M; Thompson, R, 1986)
" The median period between the beginning of significant proteinuria and the start of prednisone therapy was 5 days (range 0-194 days)."	3.67	Spontaneous remissions in frequently relapsing and steroid dependent idiopathic nephrotic syndrome. ( Müller-Wiefel, DE; Schärer, K; Wingen, AM, 1985)
"Administration of prednisone to patients with nephrotic syndromes of different aetiologies caused an abrupt increase of proteinuria."	3.66	Prednisone-induced increase of proteinuria in patients with a nephrotic syndrome. ( Gerlag, PG; Koene, RA; van Liebergen, FJ, 1983)
" Urine samples from 94 of them became protein-free during the initial 8-week course of prednisone, and the outcome for these children was good: 74 of them have been free of symptoms for at least 3 years, 18 have had relapses during the last 3 years, and only one child still has proteinuria."	3.66	Long-term outcome of primary nephrotic syndrome. ( Hallman, N; Koskimies, O; Rapola, J; Vilska, J, 1982)
"Thirty-five patients, 29 with severe proliferative glomerulonephritis and six with either steroid resistant or steroid dependent nephrotic syndrome, were treated with high dose bolus infusions of methylprednisolone (pulses) followed by prednisone given orally in more conventional doses for 6 mo or longer."	3.66	The treatment of severe glomerulopathies in children using high dose intravenous methylprednisolone pulses. ( Cole, BR; Robson, AM; Rose, GM, 1981)
"Seven patients with slight but definite proliferative changes in the glomeruli achieved complete remission of the nephrotic syndrome when treated with prednisone."	3.66	Nephrotic syndrome with slight proliferative changes in the glomeruli: response to prednisone. ( Ezedum, S; Kerr, DN; Morley, AR; Rashid, H, 1980)
" The third patient who has been on continuous prednisone therapy shows a seasonal increase in proteinuria."	3.65	Seasonal nephrotic syndrome. Description and immunological findings. ( Cameron, JS; Johansson, SG; Ogg, CS; Peters, DK; Reeves, WG; Weller, RO, 1975)
"Eighty-one adult patients with the idiopathic nephrotic syndrome were treated with prednisone, 60 to 120 mg, on alternate days."	3.65	Therapy of the idiopathic nephrotic syndrome with alternate day steroids. ( Atuk, NO; Bolton, WK; Sturgill, BC; Westervelt, FB, 1977)
"In this paper, the effect of the administration of prednisone and azathioprine on an experimental immune complex glomerulonephritis is studied."	3.65	Experimental glomerulonephritis in the rat induced by antibodies directed against tubular antigens. II. Influence of medication with prednisone and azathioprine: a histologic and immunohistologic study at the light microscopic and the ultrastructural leve ( Arends, A; Feenstra, K; Greben, HA; Hoedemaeker, PJ; van den Lee, R, 1975)
" Amelioration of proteinuria and the plasma coagulation defect followed therapy with corticosteroids and azathioprine."	3.65	Factor IX deficiency in the nephrotic syndrome: studies with prothrombin complex concentrate. ( Natelson, EA; Rahman, F; Zanger, B, 1975)
" The main adverse effects in TAC treatment were glucose intolerance, diabetes and abnormal aminotransferase."	2.84	The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy. ( Chen, J; Li, H; Li, X; Liang, Q; Qu, F; Xie, X, 2017)
"Prednisone was tapered in both groups after 1 month."	2.80	Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial. ( Barbano, G; Belingheri, M; Bodria, M; Bonanni, A; De Giovanni, D; Degl'Innocenti, L; Edefonti, A; Fornoni, A; Ghiggeri, GM; Montini, G; Murer, L; Pasini, A; Quinn, RR; Ravani, P; Reiser, J; Rossi, R; Scolari, F; Sica, F, 2015)
"Tacrolimus has been used for idiopathic membranous nephropathy (IMN) therapy, but most patients who achieved remission showed a high relapse rate when tacrolimus was withdrawn after 6-12 months of therapy."	2.78	Effect of prolonged tacrolimus treatment in idiopathic membranous nephropathy with nephrotic syndrome. ( Jia, Y; Liu, N; Luo, P; Miao, LN; Sun, GD; Yuan, H, 2013)
"Prednisone alone was administered and dose-adjusted to control extrarenal manifestations."	2.77	Renal outcome in patients with lupus nephritis using a steroid-free regimen of monthly intravenous cyclophosphamide: a prospective observational study. ( Brinks, R; Chehab, G; Fischer-Betz, R; Sander, O; Schneider, M; Voiculescu, A; Vordenbäumen, S, 2012)
"Class V lupus nephritis (LN) occurs in one-fifth of biopsy-proven cases of systemic lupus erythematosus."	2.75	Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. ( Appel, GB; Ginzler, EM; Moutzouris, DA; Radhakrishnan, J; Siempos, II; Solomons, N, 2010)
"Prednisone dose was reduced stepwise."	2.75	Mycophenolate mofetil therapy for children with steroid-resistant nephrotic syndrome. ( Duan, C; He, J; Li, Z; Wu, T; Xun, M; Yin, Y; Zhang, Y, 2010)
"Patients with biopsy-proven immunoglobulin A nephropathy with proteinuria of 1 to 5 g/d of protein."	2.74	Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. ( Chen, Y; Jiang, L; Li, G; Lv, J; Singh, AK; Wang, H; Zhang, H, 2009)
"Median proteinuria was 5."	2.74	Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. ( Austin, HA; Balow, JE; Braun, MJ; Illei, GG, 2009)
"For patients with diffuse proliferative lupus nephritis, azathioprine or cyclosporine combined with corticosteroids demonstrated equal efficacy in the prevention of flares."	2.72	A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. ( Alberighi, OD; Altieri, P; Doria, A; Ferraccioli, G; Ferrara, R; Greco, S; Manno, C; Moroni, G; Mosca, M; Ponticelli, C; Todesco, S, 2006)
" Beginning from the second LDL-A course, a dosage of 1 mg/kg/d of prednisone was administered for 6 weeks, then tapered."	2.71	A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children. ( Akioka, Y; Chikamoto, H; Fukazawa, A; Hattori, M; Ito, K; Kawaguchi, H; Khono, M; Matsunaga, A; Miyakawa, S; Nakakura, H; Ogino, D, 2003)
"Group A comprised 12 patients with IgA nephropathy, who had 24-h proteinuria of 0."	2.71	Comparison of antiproteinuric effects of two different combination therapies in children with IgA nephropathy. ( Ikeda, M; Kuwajima, H; Okada, M; Sugimoto, K; Takemura, T; Yagi, K; Yanagida, H, 2003)
"There may be a reduced risk of intussusception."	2.71	A randomized, placebo-controlled trial of prednisone in early Henoch Schönlein Purpura [ISRCTN85109383]. ( Huber, AM; King, J; Klassen, T; McLaine, P; Pothos, M, 2004)
"Forty-seven patients with lupus nephritis and abnormal serum creatinine or elevated 24-hr urine protein were enrolled."	2.69	Gallium-67 scintigraphy to predict response to therapy in active lupus nephritis. ( Lan, JL; Lin, WY; Wang, SJ, 1998)
"Eligible patients had biopsy-proven IgA nephropathy, urine protein excretion of 1."	2.69	Corticosteroids in IgA nephropathy: a randomised controlled trial. ( Altieri, P; Andrulli, S; Bolasco, PG; Fogazzi, GB; Locatelli, F; Ponticelli, C; Pozzi, C, 1999)
" Prednisolone dosage was gradually tapered to 10 mg/d at 6 months, when cyclophosphamide was replaced by azathioprine (2 mg/kg/d p."	2.69	Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression. ( Chan, KW; Chan, TM; Hao, WK; Lai, KN; Li, FK; Lui, SL; Tang, S, 1999)
"20-50% of patients with IgA nephropathy (IgAN) reach end-stage renal failure."	2.69	Long term treatment of IgA nephropathy with cyclosporine A. ( Chábová, V; Jirsa, M; Merta, M; Rychlik, I; Stejskalová, A; Tesar, V; Zabka, J, 2000)
"Twenty children and adolescents with IgA glomerulonephritis were enrolled in a crossover trial."	2.67	Double-blind, controlled trial of short-term prednisone therapy in immunoglobulin A glomerulonephritis. ( Fryer, C; Quinlan, M; Shely, E; Welch, TR; Witte, DP, 1992)
"Treatment with indomethacin, aspirin, or prednisone has been shown to reduce urinary fibrin/fibrinogen degradation products (F."	2.64	Modification by drugs of urinary fibrin/fibrinogen degradation products in glomerulonephritis. ( Cash, JD; Clarkson, AR; MacDonald, MK; Robson, JS, 1972)
"The nephrotic syndrome is discussed mainly under the aspect of predictability of the histo-pathological form of the glomerular lesions from clinical and biochemical parameters."	2.36	[Haematuria in children. II. Diagnostic problems in proteinuria and the nephrotic syndrome in childhood (author's transl)]. ( Schärer, K, 1978)
"Prednisone was discontinued, and a trial with IBD TRF-budesonide 9 mg/day started."	1.91	A pediatric case of IgA nephropathy benefitting from targeted release formulation-budesonide. ( Antonucci, L; Colucci, M; Emma, F; Vivarelli, M, 2023)
"Variation in dose and duration of corticosteroids for childhood-onset steroid-sensitive nephrotic syndrome occurs worldwide, likely reflecting the evolving evidence on optimal dosing and variable severity of the disease observed between patients."	1.62	Characteristics Associated with Variation in Corticosteroid Exposure in Children with Steroid-Sensitive Nephrotic Syndrome: Results from a Canadian Longitudinal Study. ( Brobbey, A; Chanchlani, R; Dart, AB; Lapeyraque, AL; Morgan, CJ; Nettel-Aguirre, A; Perinpanayagam, MA; Rodriguez-Lopez, S; Samuel, S; Tee, JB, 2021)
"The specific treatment regimens of IgA nephropathy (IgAN) patients with moderate proteinuria (1."	1.62	Corticosteroids could improve the renal outcome of IgA nephropathy with moderate proteinuria. ( Pei, G; Qin, W; Tan, J; Tan, L; Tang, Y; Zhong, Z, 2021)
"Crescent formation in immunoglobulin A nephropathy (IgAN) has been demonstrated to be a risk factor for worse outcomes."	1.56	Efficacy of corticosteroids in immunoglobulin A nephropathy with less than 25% crescents. ( Chen, J; Li, C; Lin, L; Liu, S; Peng, Z; Xu, H; Zhu, X, 2020)
"Idiopathic Idiopathic membranous nephropathy (iMN) is an immune-complex mediated renal disease which is usually associated with the nephrotic syndrome (NS)."	1.56	Idiopathic Membranous Nephropathy and Treatment Related Complications. ( Dzemidzic, J; Haskovic, D; Muslimovic, A; Serdarevic, N; Uncanin, S, 2020)
" Here, we explore the therapeutic potential and possible mechanisms of SAA in combination with low-dose prednisone in adriamycin (ADR)-induced minimal change disease (MCD) rat model and mouse podocyte injury cell model."	1.51	Therapeutic and antiproteinuric effects of salvianolic acid A in combined with low-dose prednisone in minimal change disease rats: Involvement of PPARγ/Angptl4 and Nrf2/HO-1 pathways. ( Fan, H; Fu, F; Gao, Z; Ji, K; Kong, L; Li, X; Liu, K; Liu, Y; Qi, D; Wang, X; Xie, H; Yu, C; Yue, G; Zhu, H, 2019)
"SLEDAI-2K ⩽ 4 with no renal activity, pleurisy, pericarditis or fever (SDI > 1; OR: 0."	1.51	Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus. ( Chatzidionysiou, K; Emamikia, S; Gomez, A; Johansson, P; Parodis, I; Soukka, S, 2019)
" Remission rate, relapse rate, and adverse events in the two groups were assessed."	1.51	Efficacy and safety of tacrolimus-based treatment for nephrotic idiopathic membranous nephropathy in young adults: A retrospective study. ( Bai, DF; Fang, W; Hu, Z; Ji, CF; Wang, L; Yuan, JZ; Zhang, J; Zhang, XJ, 2019)
"We evaluated the efficacy and safety of tacrolimus (TAC) combined with corticosteroids in treating patients with idiopathic membranous nephropathy (IMN)."	1.46	Therapy of tacrolimus combined with corticosteroids in idiopathic membranous nephropathy. ( Cui, W; Dong, W; Guan, S; Li, Q; Li, W; Liu, M; Lu, X; Luo, M; Luo, P; Miao, L; Min, X; Wang, Y, 2017)
"Median proteinuria was 145,05 ± 85,54 mg/kg/24 hours."	1.46	[Idiopathic nephrotic syndrome (INS) in children in Dakar: about 40 cases]. ( Dial, CM; Diouf, B; Ka, EHF; Keita, Y; Lemrabott, AT; Moreira, C; Ndiaye, O; Ndongo, AA; Niang, A; Niang, B; Sall, MG; Sow, A; Sylla, A, 2017)
" The aim of this study was to investigate the efficacy and safety of bortezomib combined with glucocorticoids in refractory lupus patients."	1.46	The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis. ( Hou, J; Hu, W; Huang, L; Huang, X; Liu, Z; Zhang, H; Zhou, M, 2017)
"Gender, age, and hypertension are associated with KD recurrence."	1.43	Clinicopathological features and prognosis of Kimura's disease with renal involvement in Chinese patients. ( Chen, Y; Liu, Z; Wang, J; Xu, F; Zeng, C, 2016)
"No specific treatment for IgA nephropathy (IgAN) after kidney transplantation is currently available."	1.43	Treatment protocol with pulse and oral steroids for IgA Nephropathy after kidney transplantation. ( Ariaudo, C; Biancone, L; di Vico, MC; Fop, F; Mazzucco, G; Messina, M; Segoloni, GP, 2016)
" Incidence of acute rejection, renal graft survival and SRL-related adverse effects of the immunosuppressive regimen were also observed."	1.43	[Effectiveness and safety of conversion therapy with the combination of sirolimus with low dose cyclosporine in renal transplantation recipients: a five-year clinical observation]. ( Chen, G; Ding, T; Lin, ZB; Wang, XX; Zhu, L, 2016)
"The prednisone dose was reduced stepwise during the combined treatment."	1.42	Mycophenolate mofetil therapy for steroid-resistant IgA nephropathy with the nephrotic syndrome in children. ( Ding, Y; Duan, C; Kang, Z; Li, Z; Wu, T; Xun, M; Yin, Y; Zhang, L; Zhang, Y, 2015)
"Prednisone use was statistically higher in the survivor group."	1.42	Clinicopathological features of membranoproliferative glomerulonephritis under a new classification. ( Kambham, N; Lafayette, RA; Mehta, K; Nargund, P, 2015)
"Oral prednisone 2 mg/(kg·d) was the main treatment of the first episode cases (92."	1.40	[Multicenter survey of diagnostic and therapeutic status in Chinese childhood patients with steroid-sensitive, relaping/steroid-dependent nephrotic syndrome]. ( , 2014)
"In case of pulmonary embolism or deep vein thrombosis, idiopathic-looking, a nephrotic syndrome must be sought-after."	1.40	[Nephrotic syndrome revealed by pulmonary embolism: about four cases]. ( Aupetit, JF; Chaudesaygues, E; Grasse, M; Marchand, L; Villar, E, 2014)
"Organ damage in systemic lupus erythematosus (SLE) patients is highly associated with the use of corticosteroids."	1.39	Predictors of corticosteroid tapering in SLE patients: the Hopkins Lupus Cohort. ( Fang, H; Magder, LS; Petri, M; Zahr, ZA, 2013)
" No serious adverse events were observed."	1.39	Leflunomide plus oral prednisone in treatment of idiopathic membranous nephropathy: a retrospective clinical study of efficacy and safety. ( Lu, W; Xie, L; Xue, W; Yang, S; Yin, A, 2013)
"Initial renal biopsy showed MPGN with strong C3 and immunoglobulin deposition."	1.39	Evolution of immunoglobulin deposition in C3-dominant membranoproliferative glomerulopathy. ( Kerns, E; Rozansky, D; Troxell, ML, 2013)
"Prednisone treatment significantly normalized the intensities of peaks 9069 and 15005 (which correspond to cortexin-1 and interleukin-17A, respectively, according to Swiss Prot database) by increasing the expression of 9069 but reducing expression of 15005."	1.39	Proteomic analysis indicates altered expression of plasma proteins in a rat nephropathy model. ( Ai, S; Chen, R; Lin, Q; Zheng, J, 2013)
"Proteinuria was 2."	1.38	The dynamics of urinary N-acetyl-β-D-glucosaminidase (NAG), a marker of renal tubular dysfunction, in patients with lupus nephritis undergoing oral prednisone therapy. ( Bob, F; Bozdog, G; Cioca, D; Gadalean, F; Gluhovschi, C; Gluhovschi, G; Kaycsa, A; Marian, R; Petrica, L; Velciov, S; Vernic, C, 2012)
"Non-autoimmune hypothyroidism has been reported in children with congenital nephrotic syndrome."	1.38	Hypothyroidism in children with steroid-resistant nephrotic syndrome. ( Blumenthal, D; Cleper, R; Dagan, A; Davidovits, M; Krause, I, 2012)
"Proteinuria is an important risk factor for the progression and prognosis of chronic kidney disease."	1.38	Attenuation of glomerular filtration barrier damage in adriamycin-induced nephropathic rats with bufalin: an antiproteinuric agent. ( Gan, W; Gong, J; Han, Y; Li, S; Zeng, Z; Zhang, A; Zheng, J, 2012)
"Prednisone was initiated after making the diagnosis of ISD."	1.38	Membranous nephropathy: a rare renal manifestation of IgG4-related systemic disease. ( Bastacky, S; Craig, F; Jindal, N; Krasinskas, A; Liang, KV; Passero, C; Yadav, D, 2012)
"The authors have reviewed the treatment of multiple myeloma including the novel agents, thalidomide, bortezomib and lenalidomide."	1.37	History of multiple myeloma. ( Kyle, RA; Steensma, DP, 2011)
"The treatment of membranous lupus nephritis (MLN) is still controversial in the literature."	1.37	Prednisone monotherapy induced remission in a group of patients with membranous lupus nephritis. ( Alves de Brito, G; Bitencourt Dias, C; Dos Santos Silva, V; Gera Abrão, J; Malafronte, P; Pinheiro, CC; Titan, S; Toledo Barros, R; Woronik, V, 2011)
"The nephrotic syndrome was responsive first to prednisone and finally to cyclosporine."	1.37	Incidental detection of oncocytosis in a renal biopsy specimen for idiopathic nephrotic syndrome. ( Garijo, MF; Martín-Gago, J; Rodrigo, E; Ruiz-Criado, J; Sanz, P; Val-Bernal, JF, 2011)
"13 cases were diagnosed as IMPGN by renal biopsy after excluding secondary etiology."	1.36	Combination therapy with mycophenolate mofetil and prednisone in steroid-resistant idiopathic membranoproliferative glomerulonephritis. ( Ding, X; Liu, H; Teng, J; Yuan, M; Zhang, X; Zhong, Y; Zou, J, 2010)
"Moderate proteinuria was found in 31 (66%) patients (median, 0."	1.35	Renal sarcoidosis: clinical, laboratory, and histologic presentation and outcome in 47 patients. ( Belenfant, X; Boffa, JJ; Cadranel, J; Chapelon, C; Choukroun, G; Cordonnier, C; Delastour, V; Ducroix, JP; Duhaut, P; Lescure, FX; Mahévas, M; Makdassi, R; Naccache, JM; Piette, JC; Valeyre, D, 2009)
" Most adverse events were transient and did not require change in therapy."	1.35	The effectiveness and safety of mycophenolate mofetil in lupus nephritis. ( Ballou, S; Elyan, M, 2009)
"Idiopathic membranous nephropathy (IMN) is one of the most common causes of primary nephrotic syndrome in adults."	1.34	Idiopathic membranous nephropathy in pediatric patients: presentation, response to therapy, and long-term outcome. ( Chandra, M; Chen, A; Crosby, V; Frank, R; Gauthier, B; Trachtman, H; Valderrama, E; Vento, S, 2007)
"Fourteen patients with early recurrence were treated with a protracted high-dose prednisone or IV methylprednisolone, oral cyclophosphamide, high-dose oral or IV cyclosporine, and plasma exchanges."	1.33	Recurrence of nephrotic syndrome after renal transplantation: influence of increased immunosuppression. ( André, JL; Cochat, P; Deschênes, G; Guyot, C; Loirat, C; Nathanson, S; Nivet, H, 2005)
"In the immunosuppressive treatment of lupus nephritis the insertion of a consolidation phase with rituximab combined with cyclophosphamide achieves a therapeutically important and lasting deletion of the lymphocyte clone responsible for autoimmunity."	1.32	Remission of refractory lupus nephritis with a protocol including rituximab. ( Avanzi, GC; Bartoli, E; Fra, GP, 2003)
"Treatment with azathioprine and prednisone was associated with elevated serum levels of examined lipids."	1.32	Renal function and lipid metabolism in pregnant renal transplant recipients. ( Czajkowski, K; Grymowicz, M; Malinowska-Polubiec, A; Romejko, E; Sieńko, J; Smolarczyk, R; Wójcicka-Bentyn, J, 2004)
"IgA nephropathy is one of the most common causes of glomerulonephritis in the world and is characterized histologically by the deposition of polymeric forms of IgA within the mesangium and in some cases along the glomerular capillary wall."	1.32	Clinical presentation, natural history, and treatment of crescentic proliferative IgA nephropathy. ( Hennigar, RA; Tumlin, JA, 2004)
"Although nondiabetic nephropathies are common among type 2 diabetic patients, very few cases of minimal change nephrotic syndrome have been reported in diabetic patients."	1.32	[Relapsing nephrotic syndrome in a diabetic patient with minimal change]. ( Espejo, B; García Donaire, JA; Gutiérrez Martínez, E; Manzanera, MI; Praga, M; Valentín, MO, 2004)
"We present a case of chronic lymphocytic leukemia associated with nephrotic syndrome."	1.32	Membranous glomerulonephritis in chronic lymphocytic leukemia. ( Giannouli, S; Nakopoulou, L; Psimenou, E; Voulgarelis, M; Ziakas, PD, 2004)
"We describe a patient with minimal change disease who presented with heavy proteinuria and acute renal failure but had no evidence of renal interstitial oedema on biopsy."	1.32	Minimal change disease with acute renal failure: a case against the nephrosarca hypothesis. ( Cameron, MA; Moe, OW; Peri, U; Rogers, TE, 2004)
"In primary minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS), increased lymphocyte reactivity to renal antigens has been defined."	1.30	Urinary soluble HLA class I antigen in patients with minimal change disease: a predictor of steroid response. ( Ahn, SJ; Bang, BK; Chang, YS; Choi, EJ; Kim, SY; Kim, YS; Park, CW; Shin, YS; Song, HC, 1998)
"Mean proteinuria was 9 g/day with a mean duration of disease of 25 months (range 12-48)."	1.30	A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy. ( Austin, HA; Balow, JE; Boumpas, DT; Fleisher, TA; Kim, Y; Piscitelli, S; Pucino, F; Tassiulas, IO; Vaughan, E, 1999)
"Sixteen children with biopsy-confirmed type I membranoproliferative glomerulonephritis (MPGN) were treated with six alternate-day intravenous pulses of methylprednisolone followed by single-dose alternate-day prednisone for 12-66 months (mean 37 months)."	1.29	Response of type I membranoproliferative glomerulonephritis to pulse methylprednisolone and alternate-day prednisone therapy. ( Andreoli, SP; Bergstein, JM, 1995)
"These data suggest that long-term renal function in cyclosporine-treated kidney transplant patients is primarily influenced by the occurrence of early and late rejection episodes rather than by the dosage or duration of cyclosporine therapy."	1.29	Long-term renal function in cyclosporine-treated renal allograft recipients. ( Hodge, E; Novick, AC; Streem, S; Tanabe, K, 1995)
" Dosage began at 60 mg/m2 for 3 month, was reduced to 30 mg/m2 by 1 year and 15 mg/m2 by 2 years."	1.29	Treatment of IgA nephropathy in children: efficacy of alternate-day oral prednisone. ( Benfield, MR; Herrera, GA; Kelly, DR; Kohaut, EC; Waldo, FB; Wyatt, RJ, 1993)
" The most significant factor responsible for these metabolic complications was the total dosage of prednisone and cyclosporine."	1.29	Metabolic problems in recipients of liver transplants. ( Filo, RS; Hughes, D; Jindal, RM; Leapman, SB; Lumeng, L; Milgrom, ML; Pescovitz, MD; Sidner, RA, 1996)
"In this study three new cases of recurrence of membranous nephropathy are reported."	1.29	Membranous nephropathy: recurrence after kidney transplantation. ( Mampaso, F; Marcen, R; Navarro-Antolin, J; Orofino, L; Ortuño, J; Rivera, ME; Teruel, JL, 1996)
"In 74% of the acute myeloid leukemia patients, the truncated inhibitor was detected."	1.29	Urinary excretion of proteolyzed alpha1-antitrypsin: specificity, quantitation, and relation to therapy response in patients with acute myeloid leukemia. ( Busch, R; Dengler, R; Eger, G; Emmerich, B; Münstermann, U; Plewan, A, 1995)
"The significance of the finding of focal glomerulosclerosis (FGS) in idiopathic membranous glomerulonephritis (MGN) is uncertain."	1.28	Focal glomerulosclerosis in idiopathic membranous glomerulonephritis. ( Magil, AB; Wakai, S, 1992)
"End-stage renal disease (ESRD) was secondary to chronic glomerulonephritis (n = 9), diabetes mellitus (n = 6), polycystic kidney disease (n = 5), and miscellaneous causes (n = 11)."	1.28	The development of proteinuria and focal-segmental glomerulosclerosis in recipients of pediatric donor kidneys. ( Hayes, JM; Novick, AC; Steinmuller, DR; Streem, SB, 1991)
"A young man with focal glomerulosclerosis and severe steroid resistant nephrotic syndrome was treated with oral cyclosporin for six months without histological evidence of drug induced nephrotoxicity."	1.28	Cyclosporin therapy for steroid resistant nephrotic focal glomerulosclerosis. ( Fisher, M; Neale, TJ; Windom, HH, 1990)
"The incidence of CRF or ESRD in patients with a partial response to cyclophosphamide (1 of 9) was significantly lower (p = 0."	1.27	Response to cyclophosphamide in steroid-resistant focal segmental glomerulosclerosis: a reappraisal. ( Baumal, R; Farine, M; Geary, DF; Thorner, P, 1984)
"Although this lesion resembles focal segmental glomerulosclerosis (FSGS), Howie and Brewer suggested that it constitutes a distinct entity, differing also clinically from FSGS, in that it would have a better response to steroid treatment."	1.27	The glomerular tip lesion: a distinct entity or not? ( Hené, RJ; Huppes, W; Kooiker, CJ, 1988)
"This paper reviews the four types of systemic lupus erythematosus (SLE) glomerulonephritis in children and presents the clinical and renal histologic findings."	1.26	Systemic lupus erythematosus glomerulonephritis in children. ( Donnelly, WH; Garin, EH; Richard, GA; Shulman, ST, 1981)
" The minimal steroid dosage varied from 0."	1.26	Minimum steriod requirements in renal transplant patients monitored by urinary fibrin degradation products and complement. ( Anderton, JL; Eccleston, M; Fananapazir, L, 1977)
"The nephrotic syndrome is characterized by gross proteinuria, hypoproteinemia, hyperlipemia, and edema."	1.26	Nephrotic syndrome in childhood: diagnosis and management. ( Chan, JC; Maier, BA, 1979)
"Hyperlipidemia was observed between the 4th month and the end of the first year after transplantation in 83% of the patients."	1.26	Hyperlipidemias in patients with kidney transplants. ( Brunner, F; Harder, F; Kobza, K; Stähelin, HB; Thiel, G, 1976)
"In SLE, hypertension is not necessarily associated with advanced renal disease, and high blood pressure may occur relatively early in the course of the disease."	1.26	Hypertension and renal disease in systemic lupus erythematosus. ( Budman, DR; Steinberg, AD, 1976)
"Renal vein thrombosis affected young men 2."	1.26	Renal vein thrombosis. ( Fulton, RE; Malek, RS; O'Dea, MJ; Tucker, RM, 1976)
"Urine specimens from patients with multiple myeloma and Bence Jones proteinuria frequently contain low molecular weight proteins which correspond either to the amino-terminal, variant half (VL) or to the carboxyl-terminal, constant half (CL) of the Bence Jones protein."	1.25	Bence Jones proteins and light chains of immunoglobulins. XI. A transient Bence Jones-related protein associated with corticosteroid therapy. ( Capra, JD; McLaughlin, CL; Solomon, A, 1975)

Research

Studies (426)

Authors

Clinical Trials (14)

Trial Overview

Trial Outcomes

Maintenance Phase: Events Contributing to the Primary Endpoint: Number of Deaths

Timeframe	Studies, this research(%)	All Research%
pre-1990	199 (46.71)	18.7374
1990's	60 (14.08)	18.2507
2000's	66 (15.49)	29.6817
2010's	85 (19.95)	24.3611
2020's	16 (3.76)	2.80

Authors	Studies
Li, Y	3
Fu, R	1
Gao, J	1
Wang, L	5
Duan, Z	1
Tian, L	1
Ge, H	1
Ma, X	1
Zhang, Y	4
Li, K	1
Xu, P	1
Tian, X	1
Chen, Z	1
Liu, X	3
Li, G	3
Huang, Y	1
Xun, Z	1
Song, Q	1
Wang, R	1
Wang, C	3
Rodriguez-Lopez, S	1
Chanchlani, R	1
Dart, AB	1
Morgan, CJ	1
Lapeyraque, AL	1
Tee, JB	1
Brobbey, A	1
Perinpanayagam, MA	1
Samuel, S	1
Nettel-Aguirre, A	1
Antonucci, L	1
Colucci, M	1
Emma, F	1
Vivarelli, M	1
Balestra, E	1
Barbi, E	1
Ceconi, V	1
Di Maso, V	1
Conversano, E	1
Pennesi, M	1
Chen, J	6
Xu, H	3
Peng, Z	1
Lin, L	1
Li, C	1
Zhu, X	2
Liu, S	1
Shi, Y	1
Yao, W	1
Sun, L	1
Liu, H	2
Ding, P	1
Hu, W	4
Chen, P	2
Guo, Y	1
Wu, X	3
Liu, L	1
Zhang, H	7
Yang, L	1
Chen, W	3
Lu, W	2
Gong, S	1
Li, J	1
Luo, H	1
Wang, Y	2
Oba, R	1
Koike, K	1
Okabe, M	1
Matsumoto, K	1
Tsuboi, N	1
Yokoo, T	1
Uncanin, S	1
Dzemidzic, J	1
Serdarevic, N	1
Muslimovic, A	1
Haskovic, D	1
Zhong, Z	1
Tang, Y	1
Tan, J	1
Tan, L	1
Pei, G	1
Qin, W	1
Fayed, A	1
El Menyawi, MM	1
Ghanema, M	1
Shaker, O	1
Elgohary, R	1
Zen, M	1
Fuzzi, E	1
Loredo Martinez, M	1
Depascale, R	1
Fredi, M	1
Gatto, M	1
Larosa, M	1
Saccon, F	1
Iaccarino, L	1
Doria, A	2
Pérez-Cortés, G	1
Pérez-Molina, JJ	1
Ochoa-Ponce, C	1
Ramírez-Godínez, S	1
Ornelas-Álvarez, VM	1
Ni, Z	3
Zhang, Z	1
Yu, Z	1
Lu, F	1
Mei, C	1
Ding, X	2
Yuan, W	1
Zhang, W	1
Jiang, G	2
Sun, M	2
He, L	1
Deng, Y	1
Pang, H	1
Qian, J	1
Cui, W	1
Lu, X	1
Min, X	1
Liu, M	1
Guan, S	1
Luo, M	1
Li, W	1
Li, Q	1
Dong, W	1
Miao, L	2
Luo, P	3
Bomback, AS	2
Lu, Z	1
Song, J	1
Mao, J	3
Xia, Y	2
Keita, Y	1
Lemrabott, AT	1
Sylla, A	1
Niang, B	1
Ka, EHF	1
Dial, CM	1
Ndongo, AA	1
Sow, A	1
Moreira, C	1
Niang, A	1
Ndiaye, O	1
Diouf, B	2
Sall, MG	1
Liang, Q	1
Li, H	2
Xie, X	1
Qu, F	1
Li, X	3
Maritati, F	1
Fenoglio, R	1
Pillebout, E	1
Emmi, G	1
Urban, ML	1
Rocco, R	1
Nicastro, M	1
Incerti, M	1
Goldoni, M	1
Trivioli, G	1
Silvestri, E	1
Mohammad, AJ	1
Jayne, D	1
Eriksson, P	1
Segelmark, M	1
Novikov, P	1
Harris, H	1
Roccatello, D	2
Vaglio, A	1
Avasare, RS	1
Canetta, PA	1
Marasa, M	1
Caliskan, Y	1
Ozluk, Y	1
Gharavi, AG	1
Appel, GB	3
Oliveira, B	1
Sheaff, M	1
Blunden, M	1
Wang, S	2
Pan, Q	1
Xu, C	1
Li, JJ	1
Tang, HX	1
Zou, T	1
Jing, KP	1
Ye, L	1
Wu, HL	1
Liu, WJ	1
Liu, HF	1
Castro, M	1
Ugolini-Lopes, M	1
Borba, EF	2
Bonfá, E	2
Seguro, LPC	1
Zhang, M	2
Qi, C	2
Zha, Y	1
Sun, Z	1
Wan, J	1
Xing, C	1
Chen, Q	1
Li, D	1
Guan, T	1
Maan, D	1
Clark, B	1
Bunker, M	1
Arora, S	1
Wang, X	1
Qi, D	1
Fu, F	1
Liu, Y	3
Ji, K	1
Gao, Z	1
Kong, L	1
Yu, C	1
Xie, H	1
Yue, G	1
Zhu, H	1
Liu, K	1
Fan, H	1
Parodis, I	1
Johansson, P	1
Gomez, A	1
Soukka, S	1
Emamikia, S	1
Chatzidionysiou, K	1
Zhang, XJ	1
Ji, CF	1
Yuan, JZ	1
Zhang, J	3
Fang, W	2
Bai, DF	1
Hu, Z	1
Yang, YZ	1
Liu, LJ	2
Cai, QQ	1
Shi, SF	2
Chen, YQ	2
Lv, JC	2
Pippin, JW	1
Krofft, RD	1
Naito, S	1
Liu, ZH	3
Shankland, SJ	1
Nadal, MA	1
Lococo, B	1
Fazzini, MB	1
Gonzalez, G	1
Otero, AB	1
Malvar, AV	1
Yuan, H	2
Liu, N	1
Sun, GD	1
Jia, Y	2
Miao, LN	1
Zahr, ZA	1
Fang, H	1
Magder, LS	2
Petri, M	3
Matsumoto, Y	1
Shimada, Y	1
Nojima, Y	1
Moriki, T	1
Fangtham, M	1
Yang, S	1
Xie, L	1
Xue, W	1
Yin, A	1
Kerns, E	1
Rozansky, D	1
Troxell, ML	1
Papadopoulou, V	1
Ioannou, S	1
Levidou, G	1
Variami, E	1
Kouzis, P	1
Siakantaris, M	1
Borrego-Utiel, FJ	1
Pérez-del Barrio, Mdel P	1
Polaina-Rusillo, M	1
Borrego-Hinojosa, J	1
Chen, Y	5
Bao, H	2
Liu, Z	8
Zeng, C	2
Chen, X	3
Wang, J	2
Zheng, J	4
Liu, C	1
Lin, X	2
Chaudesaygues, E	1
Grasse, M	1
Marchand, L	1
Villar, E	1
Aupetit, JF	1
Löffler, C	1
Löffler, U	1
Tuleweit, A	1
Waldherr, R	1
Uppenkamp, M	1
Bergner, R	1
Ravani, P	2
Rossi, R	1
Bonanni, A	1
Quinn, RR	1
Sica, F	1
Bodria, M	1
Pasini, A	1
Montini, G	1
Edefonti, A	2
Belingheri, M	2
De Giovanni, D	1
Barbano, G	1
Degl'Innocenti, L	1
Scolari, F	2
Murer, L	2
Reiser, J	1
Fornoni, A	1
Ghiggeri, GM	3
Kang, Z	1
Li, Z	3
Duan, C	2
Wu, T	2
Xun, M	2
Ding, Y	2
Zhang, L	1
Yin, Y	2
Hu, WX	1
Chen, YH	1
Liu, ZZ	1
Wang, SF	1
Zhang, HT	2
Jia, N	1
Cormack, FC	1
Xie, B	1
Shiue, Z	1
Najafian, B	1
Gralow, JR	1
Brookins, SM	1
Ormenisan, C	1
Makary, RF	1
Monteiro, CI	1
James, LR	1
Nargund, P	1
Kambham, N	1
Mehta, K	1
Lafayette, RA	1
Yan, SX	1
Deng, XM	1
Wang, QT	1
Sun, XJ	1
Wei, W	1
Ye, M	1
Maroz, N	1
Field, H	1
Xu, F	1
Messina, M	1
di Vico, MC	1
Ariaudo, C	1
Mazzucco, G	1
Fop, F	1
Segoloni, GP	1
Biancone, L	1
Zhu, L	2
Ding, T	1
Wang, XX	1
Lin, ZB	1
Chen, G	1
Fu, H	2
Xu, Y	1
Gu, W	1
Liu, A	2
Li, S	2
Zhou, W	1
Wang, Q	1
Mou, S	1
Shao, X	1
Huang, L	1
Hou, J	1
Zhou, M	1
Huang, X	1
Hou, JH	1
Le, WB	1
Chen, N	1
Wang, WM	1
Liu, ZS	1
Liu, D	1
Chen, JH	1
Tian, J	1
Fu, P	2
Hu, ZX	1
Zeng, CH	1
Liang, SS	1
Zhou, ML	1
Schmidt, S	1
Sears, M	1
Crawford, S	1
Cicci, C	1
Diskin, CJ	1
Lv, J	1
Jiang, L	1
Singh, AK	1
Wang, H	2
Wang, DY	1
Mao, JH	1
Gu, WZ	1
Zhao, SA	1
Chen, YF	1
Liu, AM	1
Mahévas, M	1
Lescure, FX	1
Boffa, JJ	1
Delastour, V	1
Belenfant, X	1
Chapelon, C	1
Cordonnier, C	1
Makdassi, R	1
Piette, JC	2
Naccache, JM	1
Cadranel, J	1
Duhaut, P	1
Choukroun, G	1
Ducroix, JP	1
Valeyre, D	1
Austin, HA	2
Illei, GG	1
Braun, MJ	1
Balow, JE	2
Elyan, M	1
Ballou, S	1
Wang, Z	1
Yue, XL	1
Cheng, XQ	1
Hou, WJ	1
Zhang, YY	1
Chen, DF	1
Manno, C	2
Torres, DD	1
Rossini, M	1
Pesce, F	1
Schena, FP	2
Idasiak-Piechocka, I	1
Oko, A	1
Łochyńska-Bielecka, K	1
Skrobańska, B	1
Peregud-Pogorzelski, J	1
Brodkiewicz, A	2
Szychot, E	1
Zakowska, A	1
Radhakrishnan, J	1
Moutzouris, DA	1
Ginzler, EM	1
Solomons, N	2
Siempos, II	1
Sathyan, S	1
Khan, FN	1
Ranga, KV	1
He, J	1
Gluhovschi, C	2
Gluhovschi, G	2
Herman, D	1
Trandafirescu, V	1
Petrica, L	2
Velciov, S	2
Bozdog, G	2
Bob, F	2
Cioca, D	2
Gellermann, J	1
Stefanidis, CJ	1
Mitsioni, A	1
Querfeld, U	1
Yuan, M	1
Zou, J	1
Zhang, X	1
Teng, J	1
Zhong, Y	1
Andersen, RF	1
Thrane, N	1
Noergaard, K	1
Rytter, L	1
Jespersen, B	1
Rittig, S	1
Sun, WS	1
Ren, YY	1
Zhao, YL	1
Ma, QY	1
Jauhola, O	2
Ronkainen, J	2
Koskimies, O	3
Ala-Houhala, M	2
Arikoski, P	2
Hölttä, T	2
Jahnukainen, T	2
Rajantie, J	2
Ormälä, T	2
Turtinen, J	1
Nuutinen, M	2
Hodson, EM	1
Willis, NS	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Random, Open, Control and Monocentric Clinical Research on Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy (IMN)[NCT03549663]		108 participants (Anticipated)	Interventional	2018-07-04	Recruiting
Efficacy and Safety of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)[NCT04937907]	Phase 2	50 participants (Anticipated)	Interventional	2021-09-08	Recruiting
Personalised Pharmacological Approach to the Tapering of Corticosteroid Doses in Systemic Lupus Patients Treated With Prednisone[NCT03187743]		72 participants (Actual)	Interventional	2018-04-17	Completed
Ofatumumab in Children With Steroid- and Calcineurin-inhibitor-resistant Nephrotic Syndrome: a Double-blind Randomized, Controlled, Superiority Trial[NCT02394106]	Phase 2	13 participants (Actual)	Interventional	2015-07-31	Terminated
Ofatumumab Versus Rituximab in Children With Steroid and Calcineurin Inhibitor-dependent Idiopathic Nephrotic Syndrome: an Open-label, Randomized, Controlled, Superiority Trial.[NCT02394119]	Phase 2	140 participants (Actual)	Interventional	2015-06-30	Completed
[NCT00378443]		0 participants	Interventional	2006-01-31	Active, not recruiting
Effect of Immunosuppression in IgA Nephropathy[NCT03468972]	Phase 4	174 participants (Anticipated)	Interventional	2019-03-31	Not yet recruiting
[NCT00615173]	Phase 3	81 participants (Actual)	Interventional	2006-07-31	Completed
Rituximab in Patients With Low Dose Steroid-dependent Idiopathic Nephrotic Syndrome[NCT04494438]	Phase 3	30 participants (Actual)	Interventional	2013-07-31	Completed
A Prospective, Randomized, Active Controlled, Parallel Group, Multi-center Trial to Assess the Efficacy and Safety of Mycophenolate Mofetil (MMF) in Inducing Response and Maintaining Remission in Subjects With Lupus Nephritis.[NCT00377637]	Phase 3	370 participants (Actual)	Interventional	2005-07-31	Completed
Viral Infection of Lymphoid Cells Occuring at the First Manifestation of Idiopathic Nephrotic Syndrome[NCT00577525]		401 participants (Actual)	Observational	2007-12-31	Completed
Effect and Security of Steroids Therapy for Patients of IgA Nephropathy With Crescents : A Prospective, Randomized, Controlled, Multi-Center Clinical Trial.[NCT04833374]	Phase 3	200 participants (Anticipated)	Interventional	2021-05-24	Recruiting
Phase IV Open Label Uncontrolled Trial of the Dual Blockade of the Renin Angiotensin System With Enalapril Plus Valsartan Combined With Oral Methylprednisolone for the Treatment of Proteinuria in IGA Nephropathy[NCT00367562]	Phase 4	20 participants	Interventional	1996-01-31	Completed
A Multinational Prospective Study on the Duration of Steroid Therapy in Steroid Sensitive Nephrotic Syndrome[NCT03878914]	Phase 4	34 participants (Actual)	Interventional	2019-08-06	Terminated (stopped due to The study was terminated at all but one site because of the pandemic)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Treatment Failure was adjudicated by a clinical endpoints committee (CEC) and was defined as the time to the earliest occurrence of any one of the following: death, end stage renal disease, sustained doubling of serum creatinine, renal flare, or a requirement for rescue therapy for exacerbation or deterioration of Lupus nephritis (LN). (NCT00377637)
Timeframe: From the start of the Maintenance Phase to Month 36

Maintenance Phase: Events Contributing to the Primary Endpoint: Number of Participants With End-stage Renal Disease (ESRD)

Intervention	Deaths (Number)
Mycophenolate Mofetil (MMF)	0
Azathioprine (AZA)	1

Time to treatment failure, adjudicated by the Clinical Endpoints Committee (CEC), was defined as any 1 the following: death, ESRD, sustained doubling of serum creatinine, renal flare (proteinuric or nephritic), or requirement for rescue therapy to treat deterioration or exacerbation of Lupus nephritis. ESRD is defined as progression to chronic hemodialysis or renal transplant. (NCT00377637)
Timeframe: From the start of the Maintenance Phase to Month 36

Maintenance Phase: Events Contributing to the Primary Endpoint: Number of Participants With Sustained Doubling of Serum Creatinine

Intervention	participants (Number)
Mycophenolate Mofetil (MMF)	0
Azathioprine (AZA)	3

Sustained doubling of serum creatinine concentration is defined as the first serum creatinine value that is twice the mean of the lowest 2 values from screening to end of induction, as confirmed by a second serum creatinine value obtained at least 4 weeks after the initial doubling. (NCT00377637)
Timeframe: From the start of the Maintenance Phase to Month 36

Maintenance Phase: Participants With Major Extra-renal Flare

Intervention	participants (Number)
Mycophenolate Mofetil	1
Azathioprine	5

A major extra-renal flare is defined as a British Isles Lupus Assessment Group (BILAG) Score category A in one extrarenal organ or three organs with concurrent category B scores. BILAG indices provide a scoring system for the assessment of lupus disease activity in terms of the need for steroid treatment in 8 organs/systems. Eighty-six items were scored resulting in a classification of A (severe activity), B (moderate activity), C (mild activity), D (no current activity) and E (no activity ever observed) for each organ system. (NCT00377637)
Timeframe: From the start of the Maintenance Phase to Month 36

Induction Phase: Change From Baseline in Short-Form Health Survey (SF-36) Domain and Component Scores

Intervention	participants (Number)
Mycophenolate Mofetil	7
Azathioprine	6

The SF-36 is a 36 item quality of life questionnaire. The short-form version has eleven questions that permit the participant to rate how they feel that particular day. The SF-36 consists of eight scaled scores and two component scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 score with the higher scores indicating better quality of life. (NCT00377637)
Timeframe: Baseline and 24 weeks

Induction Phase: Change From Baseline to Week 24 in 24-hour Urine Protein

Intervention	Scores on a scale (Mean)
	Physical Component Summary [n=139, 137]	Mental Component Summary [n=139, 137]	Bodily Pain Score [n=141, 137]	General Health Score [n=139, 137]	Mental Health Score [n=141, 137]	Physical functioning Score [n=141, 137]	Role-Emotional Score [n=141, 137]	Role-Physical Score [n=141, 137]	Social Function Score [n=141, 137]	Vitality Score [n=141, 137]
Intravenous Cyclophosphamide	6.4	5.7	16.8	11.5	9.8	9.3	18.4	34.0	18.2	11.6
Mycophenolate Mofetil	5.2	6.7	13.4	9.1	9.3	11.6	23.4	28.6	17.7	14.2

24-hour urine protein was measured at Baseline and Week 24. (NCT00377637)
Timeframe: Baseline, Week 24

Induction Phase: Change From Baseline to Week 24 in Serum Albumin

Induction Phase: Change From Baseline to Week 24 in Serum Creatinine

Induction Phase: Change in Renal British Isles Lupus Assessment Group (BILAG) Score

Intervention	mg/day (Mean)
	Baseline [n=180, 180]	Week 24 [n= 150, 144]	Change from Baseline to Week 24 [n= 146, 142]
Intravenous Cyclophosphamide	4451.4	1831.6	-2513.7
Mycophenolate Mofetil	4208.9	1599.0	-2510.6

Intervention	g/L (Mean)
	Baseline [n=184, 185]	Week 24 [n=155, 151]	Change from Baseline to Week 24 [n=154, 151]
Intravenous Cyclophosphamide	28.6	38.3	9.0
Mycophenolate Mofetil	30.5	38.4	7.5

Intervention	µmol/L (Mean)
	Baseline [n= 184, 185]	Week 24 [n= 155, 151]	Change from Baseline to Week 24 [n= 154, 151]
Intravenous Cyclophosphamide	92.7	83.5	-5.1
Mycophenolate Mofetil	108.6	77.6	-18.9

"BILAG indices provide a scoring system for the assessment of lupus disease activity in terms of the need for steroid treatment in 8 organs/systems. Eighty-six items were scored resulting in a classification of A (severe activity), B (moderate activity), C (mild activity), D (no current activity) and E (no activity ever observed) for each organ system. The BILAG individual system summaries were calculated by a program supplied by ADS-Limathon (Sheffield, UK).~The score at baseline was compared to the score at the 24 week endpoint for each treatment group, reported here for the renal system." (NCT00377637)
Timeframe: Baseline, 24 weeks

Induction Phase: Number of Participants Achieving Complete Remission

Intervention	Percentage of participants (Number)
	Shift from Baseline=A to 24 Week Endpoint=A	Shift from Baseline=A to 24 Week Endpoint=B	Shift from Baseline=A to 24 Week Endpoint=C	Shift from Baseline=A to 24 Week Endpoint=D	Shift from Baseline=B to 24 Week Endpoint=A	Shift from Baseline=B to 24 Week Endpoint=B	Shift from Baseline=B to 24 Week Endpoint=C	Shift from Baseline=B to 24 Week Endpoint=D	Shift from Baseline=C to 24 Week Endpoint=A	Shift from Baseline=C to 24 Week Endpoint=B	Shift from Baseline=C to 24 Week Endpoint=C	Shift from Baseline=C to 24 Week Endpoint=D	Shift from Baseline=D to 24 Week Endpoint=A	Shift from Baseline=D to 24 Week Endpoint=B	Shift from Baseline=D to 24 Week Endpoint=C	Shift from Baseline=D to 24 Week Endpoint=D
Intravenous Cyclophosphamide	27.1	34.8	24.9	9.4	0.0	1.1	1.7	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.6	0.0
Mycophenolate Mofetil	17.1	39.2	33.1	5.5	0.0	1.7	2.2	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Number of participants achieving complete remission as defined by return to normal serum creatinine, proteinuria ≤500 mg/24 hours and an inactive urinary sediment (absence of red blood cells, white blood cells or cellular or granular casts) after 24 weeks. (NCT00377637)
Timeframe: 24 weeks

Induction Phase: Number of Patients Showing Treatment Response

Intervention	participants (Number)
	Complete Remission - Yes	Complete Remission - No
Intravenous Cyclophosphamide	15	170
Mycophenolate Mofetil	16	169

Treatment response was adjudicated by a blinded clinical endpoints committee (CEC) and defined as: a) Decrease in proteinuria, defined as a decrease in the urine protein to creatinine ratio (UPCr) to <3 in subjects with baseline proteinuria ≥3 UPCr or a decrease in the UPCr by ≥50% in subjects with proteinuria <3 UPCr at Baseline, and b) Stabilization of serum creatinine or improvement. UPCr were derived from the 24 hour urine collection. Patients who did not show a treatment response at Week 24 or who withdrew earlier than Week 24 were considered non-responders. (NCT00377637)
Timeframe: 24 weeks

Maintenance Phase: Events Contributing to the Primary Endpoint: Kaplan-Meier Estimates of Percentage of Participants Not Receiving Rescue Therapy

Intervention	participants (Number)
	Responder	Non-responder
Intravenous Cyclophosphamide	98	87
Mycophenolate Mofetil	104	81

The primary efficacy parameter was the time to treatment failure, adjudicated by the Clinical Endpoints Committee (CEC), defined as any of the following: death, end stage renal disease, sustained doubling of serum creatinine, renal flare, or requirement for rescue therapy to treat deterioration or exacerbation of Lupus nephritis. Kaplan-Meier survival curves were estimated from the observed time to rescue treatment for each patient. The data presented are the percentage of participants who were rescue treatment free at each time interval as estimated by Kaplan-Meier. (NCT00377637)
Timeframe: From the start of the Maintenance Phase to Month 36

Maintenance Phase: Events Contributing to the Primary Endpoint: Kaplan-Meier Estimates of Percentage of Participants Renal Flare Free, by Time Interval

Intervention	Percentage of participants (Number)
	Start of Maintenance Phase to Month 3	Month 3 to Month 6	Month 6 to Month 9	Month 9 to Month 12	Month 12 to Month 15	Month 15 to Month 18	Month 18 to Month 21	Month 21 to Month 24	Month 24 to Month 27	Month 27 to Month 30	Month 30 to Month 33	Month 33 to Month 36
Azathioprine	99.1	95.1	93.0	91.9	88.4	87.1	83.1	83.1	81.7	80.3	78.8	75.9
Mycophenolate Mofetil	100	98.2	97.2	94.2	94.2	94.2	93.1	91.9	90.8	90.8	90.8	90.8

A proteinuric flare is defined as a doubling of the urine protein:creatinine ratio, and proteinuria ≥1 g/24 h in patients with urine protein ≤0.5 g/24 h at the end of the induction phase, or proteinuria ≥2 g/24 h if urine protein was >0.5 g/24 h at the end of the induction phase. A nephritic flare is defined as a 25% increase in serum creatinine accompanied by 1 or more of the following: (a) simultaneous doubling of the proteinuria reaching a minimum of 2 g/24 h (b) new/increased hematuria or (c) the appearance of cellular casts. All flares were adjudicated by a clinical endpoints committee. (NCT00377637)
Timeframe: From the start of the Maintenance Phase to Month 36

Maintenance Phase: Kaplan-Meier Estimates of Percentage of Participants Treatment Failure Free, by Time Interval

Intervention	Percentage of participants (Number)
	Start of Maintenance Phase to Month 3	Month 3 to Month 6	Month 6 to Month 9	Month 9 to Month 12	Month 12 to Month 15	Month 15 to Month 18	Month 18 to Month 21	Month 21 to Month 24	Month 24 to Month 27	Month 27 to Month 30	Month 30 to Month 33	Month 33 to Month 36
Azathioprine	97.2	90.3	87.2	85.0	82.8	79.2	78.0	75.5	74.2	74.2	72.9	70.1
Mycophenolate Mofetil	98.2	94.6	90.8	87.8	87.8	86.8	86.8	86.8	86.8	86.8	85.6	85.6

Treatment Failure was adjudicated by a clinical endpoints committee and was defined as the time to the earliest occurrence of any one of the following: death, end stage renal disease, sustained doubling of serum creatinine, renal flare, or a requirement for rescue therapy for exacerbation or deterioration of Lupus nephritis. Kaplan-Meier survival curves were estimated from the observed time to treatment failure for each patient. The data presented are the percentage of participants who were treatment-failure free at each time interval as estimated by Kaplan-Meier. (NCT00377637)
Timeframe: From the start of the Maintenance Phase to Month 36

Article	Year
Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis. Medicine, 2020, Volume: 99, Issue:16 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agen	2020
2013 update: Hopkins lupus cohort. Current rheumatology reports, 2013, Volume: 15, Issue:9 Topics: Antirheumatic Agents; Cardiovascular Diseases; Cognition Disorders; Cohort Studies; Creatinine; Gluc	2013
Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature. BMC cancer, 2015, Jul-22, Volume: 15 Topics: Administration, Oral; Adult; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Dip	2015
Kimura disease: a case report and review of the Chinese literature. Nephron. Clinical practice, 2009, Volume: 111, Issue:1 Topics: Adolescent; Adult; Angiolymphoid Hyperplasia with Eosinophilia; Biopsy; Child; Child, Preschool; Chi	2009
Interventions for idiopathic steroid-resistant nephrotic syndrome in children. The Cochrane database of systematic reviews, 2010, Nov-10, Issue:11 Topics: Adolescent; Angiotensin-Converting Enzyme Inhibitors; Azathioprine; Child; Child, Preschool; Cycloph	2010
BIOCHEMISTRY OF THE NEPHROTIC SYNDROME. Biochemical clinics, 1963, Volume: 2 Topics: Adolescent; Blood Protein Disorders; Child; Creatine; Creatinine; Edema; Humans; Hyperlipidemias; Hy	1963
Adolescents with proteinuria and/or the nephrotic syndrome. Adolescent medicine clinics, 2005, Volume: 16, Issue:1 Topics: Adolescent; Cardiovascular Diseases; Comorbidity; Glucocorticoids; Humans; Nephrotic Syndrome; Predn	2005
Focal and segmental glomerulosclerosis and plasma cell proliferative disorders. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2005, Volume: 46, Issue:2 Topics: Aged; Amyloidosis; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; C	2005
Kidney involvement in multiple myeloma and related disorders. Contributions to nephrology, 1982, Volume: 33 Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Amyloidosis; Bence Jones Protein; Cyclophosphamide; Fe	1982
Proteinuria. Pediatric annals, 1996, Volume: 25, Issue:5 Topics: Adolescent; Anti-Inflammatory Agents; Biopsy; Child; Child, Preschool; Clinical Protocols; Diagnosis	1996
[Immunosuppressive treatment of patients with a nephrotic syndrome due to minimal change glomerulopathy]. Nederlands tijdschrift voor geneeskunde, 1998, Dec-26, Volume: 142, Issue:52 Topics: Adolescent; Adrenal Cortex Hormones; Adult; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammat	1998
Nephrotic syndrome: pathogenesis and management. Pediatrics in review, 2002, Volume: 23, Issue:7 Topics: Albumins; Biopsy; Child; Diuretics; Glucocorticoids; Humans; Kidney; Nephrotic Syndrome; Prednisone;	2002
[Haematuria in children. II. Diagnostic problems in proteinuria and the nephrotic syndrome in childhood (author's transl)]. Monatsschrift fur Kinderheilkunde, 1978, Volume: 126, Issue:2 Topics: Adolescent; Biopsy; Child; Child, Preschool; Glomerulonephritis; Humans; Kidney; Kidney Glomerulus;	1978
Management of the nephrotic syndrome in children. Pediatric clinics of North America, 1976, Volume: 23, Issue:4 Topics: Child; Cyclophosphamide; Diagnosis, Differential; Dose-Response Relationship, Drug; Female; Humans;	1976
Treatment of proteinuric idiopathic glomerulonephritides in adults: a retrospective survey. The American journal of medicine, 1988, Volume: 85, Issue:3 Topics: Azathioprine; Cyclophosphamide; Glomerulonephritis; Humans; Prednisone; Proteinuria; Retrospective S	1988
Long-term prognosis of diffuse lupus nephritis. Clinical nephrology, 1987, Volume: 28, Issue:6 Topics: Administration, Oral; Adolescent; Adult; Creatinine; Female; Follow-Up Studies; Humans; Infusions, I	1987
Immunosuppressant agents in the treatment of glomerulonephritis. 1. Corticosteroid drugs. Journal of the Royal College of Physicians of London, 1971, Volume: 5, Issue:3 Topics: Adrenocorticotropic Hormone; Betamethasone; Biopsy; Child; Dexamethasone; Drug Resistance; Glomerulo	1971
Management of the nephrotic syndrome. Clinical pediatrics, 1974, Volume: 13, Issue:1 Topics: Adolescent; Azathioprine; Child; Child, Preschool; Chlorambucil; Clinical Trials as Topic; Cyclophos	1974
Counseling the pregnant patient with renal disease. Clinical obstetrics and gynecology, 1968, Volume: 11, Issue:2 Topics: Abortion, Therapeutic; Acute Kidney Injury; Attitude to Health; Biopsy; Counseling; Delivery, Obstet	1968
[Therapy of paraproteinemic diseases]. Deutsches medizinisches Journal, 1968, Aug-05, Volume: 19, Issue:15 Topics: Allopurinol; Androstanes; Antineoplastic Agents; Blood Proteins; Cyclophosphamide; Follow-Up Studies	1968

Article	Year
Effect of pulsed intravenous methylprednisolone with alternative low-dose prednisone on high-risk IgA nephropathy: a 18-month prospective clinical trial. Scientific reports, 2022, 01-07, Volume: 12, Issue:1 Topics: Administration, Intravenous; Administration, Oral; Adult; Disease Progression; Drug Tapering; Drug T	2022
Efficacy of leflunomide combined with prednisone for the treatment of PLA2R-associated primary membranous nephropathy. Renal failure, 2020, Volume: 42, Issue:1 Topics: Adult; Autoantibodies; Biomarkers; Cyclophosphamide; Drug Therapy, Combination; Female; Glomerulonep	2020
Leflunomide plus low-dose prednisone in patients with progressive IgA nephropathy: a multicenter, prospective, randomized, open-labeled, and controlled trial. Renal failure, 2021, Volume: 43, Issue:1 Topics: Adult; China; Creatinine; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glomerulone	2021
The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy. Renal failure, 2017, Volume: 39, Issue:1 Topics: Adult; Cyclophosphamide; Diabetes Mellitus; Drug Therapy, Combination; Female; Glomerular Filtration	2017
Massive Proteinuria-Induced Injury of Tubular Epithelial Cells in Nephrotic Syndrome is Not Exacerbated by Furosemide. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2018, Volume: 45, Issue:4 Topics: Adolescent; Adult; Biomarkers; Case-Control Studies; Cell Line; Cell Survival; Child; Epithelial Cel	2018
Effectiveness of renoprotective approaches for persistent proteinuria in lupus nephritis: more than just immunosuppression. Lupus, 2018, Volume: 27, Issue:14 Topics: Adult; Azathioprine; Blood Pressure; Brazil; Drug Therapy, Combination; Female; Humans; Immunosuppre	2018
Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial. Clinical rheumatology, 2019, Volume: 38, Issue:3 Topics: Adult; Antibodies, Antinuclear; China; Complement C3; Cyclophosphamide; DNA; Drug Therapy, Combinati	2019
Effect of prolonged tacrolimus treatment in idiopathic membranous nephropathy with nephrotic syndrome. Pharmacology, 2013, Volume: 91, Issue:5-6 Topics: Adult; Drug Therapy, Combination; Female; Glomerulonephritis, Membranous; Humans; Immunosuppressive	2013
Efficacy of mizoribine followed by low-dose prednisone in patients with idiopathic membranous nephropathy and nephrotic-range proteinuria. Renal failure, 2013, Volume: 35, Issue:7 Topics: Adult; Aged; Creatinine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monito	2013
Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial. Journal of the American Society of Nephrology : JASN, 2015, Volume: 26, Issue:9 Topics: Adolescent; Anti-Inflammatory Agents; Child; Child, Preschool; Female; Humans; Immunologic Factors;	2015
Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial. Journal of the American Society of Nephrology : JASN, 2015, Volume: 26, Issue:9 Topics: Adolescent; Anti-Inflammatory Agents; Child; Child, Preschool; Female; Humans; Immunologic Factors;	2015
Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial. Journal of the American Society of Nephrology : JASN, 2015, Volume: 26, Issue:9 Topics: Adolescent; Anti-Inflammatory Agents; Child; Child, Preschool; Female; Humans; Immunologic Factors;	2015
Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial. Journal of the American Society of Nephrology : JASN, 2015, Volume: 26, Issue:9 Topics: Adolescent; Anti-Inflammatory Agents; Child; Child, Preschool; Female; Humans; Immunologic Factors;	2015
Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017, Volume: 69, Issue:6 Topics: Adult; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glomerulonephritis, IGA; Gluco	2017
Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2009, Volume: 53, Issue:1 Topics: Adrenal Cortex Hormones; Adult; Angiotensin-Converting Enzyme Inhibitors; Biopsy; Cilazapril; Creati	2009
Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2009, Volume: 53, Issue:1 Topics: Adrenal Cortex Hormones; Adult; Angiotensin-Converting Enzyme Inhibitors; Biopsy; Cilazapril; Creati	2009
Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2009, Volume: 53, Issue:1 Topics: Adrenal Cortex Hormones; Adult; Angiotensin-Converting Enzyme Inhibitors; Biopsy; Cilazapril; Creati	2009
Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2009, Volume: 53, Issue:1 Topics: Adrenal Cortex Hormones; Adult; Angiotensin-Converting Enzyme Inhibitors; Biopsy; Cilazapril; Creati	2009
Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. Journal of the American Society of Nephrology : JASN, 2009, Volume: 20, Issue:4 Topics: Adolescent; Adult; Age of Onset; Cyclophosphamide; Cyclosporine; Female; Hematocrit; Humans; Immunos	2009
Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2009, Volume: 24, Issue:12 Topics: Adrenal Cortex Hormones; Adult; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination;	2009
Efficacy and safety of low-dose chlorambucil in nephrotic patients with idiopathic membranous nephropathy. Kidney & blood pressure research, 2009, Volume: 32, Issue:4 Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Female; Follow-Up	2009
Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney international, 2010, Volume: 77, Issue:2 Topics: Adolescent; Adult; Creatinine; Cyclophosphamide; Female; Glucocorticoids; Humans; Immunosuppressive	2010
Mycophenolate mofetil therapy for children with steroid-resistant nephrotic syndrome. Pediatric nephrology (Berlin, Germany), 2010, Volume: 25, Issue:5 Topics: Child, Preschool; Cholesterol; Drug Resistance; Female; Humans; Immunosuppressive Agents; Infant; Ma	2010
Renal manifestations of Henoch-Schonlein purpura in a 6-month prospective study of 223 children. Archives of disease in childhood, 2010, Volume: 95, Issue:11 Topics: Adolescent; Age Distribution; Age of Onset; Child; Child, Preschool; Epidemiologic Methods; Glucocor	2010
Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2011, Volume: 57, Issue:2 Topics: Adult; Anti-Inflammatory Agents; China; Creatinine; Cyclophosphamide; Drug Therapy, Combination; Fem	2011
Outcome of Henoch-Schönlein purpura 8 years after treatment with a placebo or prednisone at disease onset. Pediatric nephrology (Berlin, Germany), 2012, Volume: 27, Issue:6 Topics: Adolescent; Adult; Blood Pressure; Chi-Square Distribution; Child; Double-Blind Method; Female; Finl	2012
Rituximab in children with resistant idiopathic nephrotic syndrome. Journal of the American Society of Nephrology : JASN, 2012, Volume: 23, Issue:6 Topics: Adolescent; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Calcineurin In	2012
Rituximab in children with resistant idiopathic nephrotic syndrome. Journal of the American Society of Nephrology : JASN, 2012, Volume: 23, Issue:6 Topics: Adolescent; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Calcineurin In	2012
Rituximab in children with resistant idiopathic nephrotic syndrome. Journal of the American Society of Nephrology : JASN, 2012, Volume: 23, Issue:6 Topics: Adolescent; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Calcineurin In	2012
Rituximab in children with resistant idiopathic nephrotic syndrome. Journal of the American Society of Nephrology : JASN, 2012, Volume: 23, Issue:6 Topics: Adolescent; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Calcineurin In	2012
Rituximab in children with resistant idiopathic nephrotic syndrome. Journal of the American Society of Nephrology : JASN, 2012, Volume: 23, Issue:6 Topics: Adolescent; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Calcineurin In	2012
Rituximab in children with resistant idiopathic nephrotic syndrome. Journal of the American Society of Nephrology : JASN, 2012, Volume: 23, Issue:6 Topics: Adolescent; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Calcineurin In	2012
Rituximab in children with resistant idiopathic nephrotic syndrome. Journal of the American Society of Nephrology : JASN, 2012, Volume: 23, Issue:6 Topics: Adolescent; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Calcineurin In	2012
Rituximab in children with resistant idiopathic nephrotic syndrome. Journal of the American Society of Nephrology : JASN, 2012, Volume: 23, Issue:6 Topics: Adolescent; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Calcineurin In	2012
Rituximab in children with resistant idiopathic nephrotic syndrome. Journal of the American Society of Nephrology : JASN, 2012, Volume: 23, Issue:6 Topics: Adolescent; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Calcineurin In	2012
Efficacy of mycophenolate mofetil in adolescent patients with lupus nephritis: evidence from a two-phase, prospective randomized trial. Lupus, 2012, Volume: 21, Issue:13 Topics: Administration, Oral; Adolescent; Age Factors; Asia; Azathioprine; Biomarkers; Creatinine; Cyclophos	2012
Renal outcome in patients with lupus nephritis using a steroid-free regimen of monthly intravenous cyclophosphamide: a prospective observational study. The Journal of rheumatology, 2012, Volume: 39, Issue:11 Topics: Administration, Intravenous; Adrenal Cortex Hormones; Adult; Creatinine; Cyclophosphamide; Dose-Resp	2012
Steroid withdrawal from tacrolimus-based therapy in renal transplant patients. Transplantation proceedings, 2002, Volume: 34, Issue:5 Topics: Adrenal Cortex Hormones; Creatinine; Drug Administration Schedule; Europe; Graft Rejection; Humans;	2002
Renal transplantation: can we reduce calcineurin inhibitor/stop steroids? Evidence based on protocol biopsy findings. Journal of the American Society of Nephrology : JASN, 2003, Volume: 14, Issue:3 Topics: Adult; Azathioprine; Biopsy; Calcineurin Inhibitors; Chronic Disease; Cyclosporine; Drug Therapy, Co	2003
A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2003, Volume: 42, Issue:6 Topics: Adolescent; Blood Component Removal; Cellulose; Child; Combined Modality Therapy; Cyclosporine; Dext	2003
Comparison of antiproteinuric effects of two different combination therapies in children with IgA nephropathy. Clinical and experimental nephrology, 2003, Volume: 7, Issue:4 Topics: Adolescent; Adult; Age of Onset; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents;	2003
A randomized, placebo-controlled trial of prednisone in early Henoch Schönlein Purpura [ISRCTN85109383]. BMC medicine, 2004, Apr-02, Volume: 2 Topics: Abdominal Pain; Administration, Oral; Child; Child, Preschool; Double-Blind Method; Female; Gastroin	2004
Prednisone/cyclophosphamide treatment in adult-onset autosomal dominant familial focal segmental glomerulosclerosis (FSGS 1). Clinical nephrology, 2006, Volume: 65, Issue:6 Topics: Administration, Oral; Adult; Age of Onset; Chromosome Disorders; Creatinine; Cyclophosphamide; Dose-	2006
[Insulinsensitivity and beta-cell function in children with idiopathic nephrotic syndrome]. Przeglad lekarski, 2006, Volume: 63 Suppl 3 Topics: Adolescent; Blood Glucose; Child; Child, Preschool; Female; Glucocorticoids; Humans; Insulin; Insuli	2006
Combined therapy of low-dose tacrolimus and prednisone in nephrotic syndrome with slight mesangial proliferation. Nephrology (Carlton, Vic.), 2006, Volume: 11, Issue:5 Topics: Adult; Cell Division; Cholesterol; Drug Therapy, Combination; Female; Glomerular Mesangium; Glucocor	2006
Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: comparison of two CNI-free protocols. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2007, Volume: 22, Issue:8 Topics: Aged; Calcineurin Inhibitors; Graft Survival; Humans; Immunosuppression Therapy; Immunosuppressive A	2007
Mycophenolate mofetil treatment for therapy-resistant glomerulopathies. Nephrology (Carlton, Vic.), 2007, Volume: 12, Issue:3 Topics: Adolescent; Adult; Creatine; Female; Glomerular Filtration Rate; Glomerulonephritis; Humans; Kidney	2007
A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clinical journal of the American Society of Nephrology : CJASN, 2006, Volume: 1, Issue:5 Topics: Administration, Oral; Adult; Azathioprine; Complement C3; Complement C4; Creatinine; Cyclophosphamid	2006
[The effect of cyclosporine A in steroid-dependent nephrotic syndrome in children]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2005, Volume: 18, Issue:104 Topics: Adolescent; Child; Cyclosporine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans	2005
Childhood nephrotic syndrome associated with diffuse mesangial hypercellularity. A report of the Southwest Pediatric Nephrology Study Group. Kidney international, 1983, Volume: 24, Issue:1 Topics: Child; Child, Preschool; Female; Hematuria; Humans; Hyperplasia; Hypertension, Renal; Immunoglobulin	1983
Report on the second myelomatosis trial after five years of follow-up. Medical Research Council's Working Party on Leukaemia in Adults. British journal of cancer, 1980, Volume: 42, Issue:6 Topics: Aged; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Follow-Up Studies; Hemo	1980
The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients. Journal of the American Society of Nephrology : JASN, 1995, Volume: 5, Issue:12 Topics: Adult; Apolipoproteins; Arteriosclerosis; Azathioprine; Cholesterol, HDL; Cyclosporine; Female; Graf	1995
Long-term benefits and risks of cyclosporin A (sandimmun)--an analysis at 10 years. Transplantation proceedings, 1994, Volume: 26, Issue:5 Topics: Antihypertensive Agents; Azathioprine; Blood Pressure; Cadaver; Creatinine; Cyclosporine; Drug Thera	1994
Idiopathic membranous nephropathy in the elderly. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1993, Volume: 8, Issue:12 Topics: Adolescent; Adult; Aged; Chlorambucil; Creatinine; Drug Therapy, Combination; Female; Glomerulonephr	1993
Alternate-day prednisone therapy in IgA nephropathy. Preliminary analysis of a prospective, randomized, controlled trial. Contributions to nephrology, 1993, Volume: 104 Topics: Adolescent; Adult; Creatinine; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Glom	1993
[Initial therapy of primary nephrotic syndrome in children: evaluation in a period of 18 months of two prednisone treatment schedules. Chilean Co-operative Group of Study of Nephrotic Syndrome in Children]. Revista medica de Chile, 1996, Volume: 124, Issue:5 Topics: Adolescent; Biopsy; Child; Child, Preschool; Follow-Up Studies; Humans; Infant; Kidney; Nephrotic Sy	1996
Response of crescentic Henoch-Schoenlein purpura nephritis to corticosteroid and azathioprine therapy. Clinical nephrology, 1998, Volume: 49, Issue:1 Topics: Adolescent; Azathioprine; Child; Child, Preschool; Creatinine; Drug Therapy, Combination; Female; Gl	1998
Gallium-67 scintigraphy to predict response to therapy in active lupus nephritis. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1998, Volume: 39, Issue:12 Topics: Adult; Aged; Creatinine; Cyclophosphamide; Female; Follow-Up Studies; Gallium Radioisotopes; Humans;	1998
Antioxidant status of children with steroid-sensitive nephrotic syndrome. Pediatric nephrology (Berlin, Germany), 1998, Volume: 12, Issue:9 Topics: Adolescent; Anti-Inflammatory Agents; Antioxidants; Ascorbic Acid; Child; Child, Preschool; Choleste	1998
Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet (London, England), 1999, Mar-13, Volume: 353, Issue:9156 Topics: Administration, Oral; Adolescent; Adult; Aged; Creatinine; Drug Administration Schedule; Female; Glo	1999
Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet (London, England), 1999, Mar-13, Volume: 353, Issue:9156 Topics: Administration, Oral; Adolescent; Adult; Aged; Creatinine; Drug Administration Schedule; Female; Glo	1999
Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet (London, England), 1999, Mar-13, Volume: 353, Issue:9156 Topics: Administration, Oral; Adolescent; Adult; Aged; Creatinine; Drug Administration Schedule; Female; Glo	1999
Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet (London, England), 1999, Mar-13, Volume: 353, Issue:9156 Topics: Administration, Oral; Adolescent; Adult; Aged; Creatinine; Drug Administration Schedule; Female; Glo	1999
Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet (London, England), 1999, Mar-13, Volume: 353, Issue:9156 Topics: Administration, Oral; Adolescent; Adult; Aged; Creatinine; Drug Administration Schedule; Female; Glo	1999
Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet (London, England), 1999, Mar-13, Volume: 353, Issue:9156 Topics: Administration, Oral; Adolescent; Adult; Aged; Creatinine; Drug Administration Schedule; Female; Glo	1999
Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet (London, England), 1999, Mar-13, Volume: 353, Issue:9156 Topics: Administration, Oral; Adolescent; Adult; Aged; Creatinine; Drug Administration Schedule; Female; Glo	1999
Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet (London, England), 1999, Mar-13, Volume: 353, Issue:9156 Topics: Administration, Oral; Adolescent; Adult; Aged; Creatinine; Drug Administration Schedule; Female; Glo	1999
Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet (London, England), 1999, Mar-13, Volume: 353, Issue:9156 Topics: Administration, Oral; Adolescent; Adult; Aged; Creatinine; Drug Administration Schedule; Female; Glo	1999
Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression. Lupus, 1999, Volume: 8, Issue:7 Topics: Adult; Alopecia; Anti-Inflammatory Agents; Azathioprine; Cohort Studies; Cyclophosphamide; Drug Ther	1999
Long term treatment of IgA nephropathy with cyclosporine A. Renal failure, 2000, Volume: 22, Issue:1 Topics: Adult; Cyclosporine; Female; Glomerulonephritis, IGA; Glucocorticoids; Humans; Male; Prednisone; Pro	2000
Steroid and cyclophosphamide in IgA nephropathy. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2000, Volume: 15, Issue:6 Topics: Adolescent; Adult; Aged; Cyclophosphamide; Drug Therapy, Combination; Female; Glomerulonephritis, IG	2000
Urinary retinol-binding protein as a prognostic marker in the treatment of nephrotic syndrome. Nephron, 2000, Volume: 86, Issue:2 Topics: Adolescent; Adult; Azathioprine; Biomarkers; Child; Creatinine; Cyclophosphamide; Cyclosporine; Fema	2000
Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney international, 2001, Volume: 59, Issue:4 Topics: Adult; Cyclosporine; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; F	2001
[Cyclophosphamide pulse therapy in patients with primary glomerulonephritis]. Przeglad lekarski, 2000, Volume: 57, Issue:11 Topics: Adult; Biopsy; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combination; Female; Gl	2000
Management of massive proteinuria following renal transplantation with mycophenolate mofetil and blood pressure normalization. Transplantation proceedings, 2001, Volume: 33, Issue:3 Topics: Azathioprine; Biopsy; Blood Pressure; Cholesterol; Creatinine; Cyclosporine; Drug Therapy, Combinati	2001
[Evaluation of prednisone treatment in children with IgA nephropathy and Schönlein-Henoch nephropathy according to the Waldo protocol with regard to pathomorphologic changes in renal biopsy]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2001, Volume: 10, Issue:58 Topics: Adolescent; Anti-Inflammatory Agents; Biopsy; Child; Child, Preschool; Drug Administration Schedule;	2001
Cytostatic treatment of glomerular diseases. IV. The effect of combined immunosuppressive treatment on serum creatinine and proteinuria evaluated by sequential statistical analysis. Report from a Copenhagen study group of renal diseases. Acta medica Scandinavica, 1978, Volume: 203, Issue:5 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Azathioprine; Child; Clinical Trials as Topic; Creat	1978
Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo. Blood, 1978, Volume: 52, Issue:4 Topics: Alkaline Phosphatase; Amyloidosis; Blood Coagulation; Clinical Trials as Topic; Creatinine; Double-B	1978
A controlled study of short-term prednisone treatment in adults with membranous nephropathy. The New England journal of medicine, 1979, 12-13, Volume: 301, Issue:24 Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Female; Glomerular Filtration Rate; Glomeruloneph	1979
Progression from minimal or focal to diffuse proliferative lupus nephritis. Laboratory investigation; a journal of technical methods and pathology, 1975, Volume: 32, Issue:5 Topics: Adolescent; Adult; Azathioprine; Child; Clinical Trials as Topic; Cyclophosphamide; Female; Glomerul	1975
Cyclophosphamide or azathioprine in lupus glomerulonephritis. A controlled trial: results at 28 months. Annals of internal medicine, 1975, Volume: 83, Issue:5 Topics: Adolescent; Adult; Amenorrhea; Azathioprine; Child; Clinical Trials as Topic; Complement C3; Cycloph	1975
Ciclosporin plus steroids versus steroids alone in the treatment of lupus nephritis. Contributions to nephrology, 1992, Volume: 99 Topics: Creatinine; Cyclosporine; Drug Therapy, Combination; Humans; Lupus Nephritis; Prednisone; Proteinuri	1992
Double-blind, controlled trial of short-term prednisone therapy in immunoglobulin A glomerulonephritis. The Journal of pediatrics, 1992, Volume: 121, Issue:3 Topics: Adolescent; Child; Creatinine; Double-Blind Method; Female; Glomerulonephritis, IGA; Hematuria; Huma	1992
Lipid metabolic abnormalities after renal transplantation under cyclosporine and prednisone immunosuppression. Transplantation proceedings, 1992, Volume: 24, Issue:1 Topics: Adult; Antilymphocyte Serum; Apolipoproteins; Cholesterol; Cyclosporine; Female; Follow-Up Studies;	1992
Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone--a report of the International Study of Kidney Disease in Children. Pediatric nephrology (Berlin, Germany), 1992, Volume: 6, Issue:2 Topics: Adolescent; Child; Child, Preschool; Double-Blind Method; Drug Administration Schedule; Female; Glom	1992
A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy. The New England journal of medicine, 1989, Jan-26, Volume: 320, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Creatinine; Drug Administratio	1989
A controlled trial of cyclophosphamide in patients with membranous glomerulonephritis. Kidney international, 1987, Volume: 32, Issue:4 Topics: Adult; Aged; Basement Membrane; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combinatio	1987
Adult minimal change nephropathy: experience of the collaborative study of glomerular disease. Transactions of the American Clinical and Climatological Association, 1986, Volume: 97 Topics: Adult; Clinical Trials as Topic; Follow-Up Studies; Humans; Kidney Glomerulus; Nephrosis, Lipoid; Pr	1986
Cyclophosphamide in lupus nephritis: a controlled trial. Annals of internal medicine, 1971, Volume: 75, Issue:2 Topics: Administration, Oral; Adolescent; Adult; Antibodies, Antinuclear; Biopsy; Child; Clinical Trials as	1971
Prospective, controlled trial of cyclophosphamide therapy in children with nephrotic syndrome. Report of the International study of Kidney Disease in Children. Lancet (London, England), 1974, Aug-24, Volume: 2, Issue:7878 Topics: Adolescent; Age Factors; Alopecia; Child; Child, Preschool; Cyclophosphamide; Cystitis; Drug Evaluat	1974
Management of the nephrotic syndrome. Clinical pediatrics, 1974, Volume: 13, Issue:1 Topics: Adolescent; Azathioprine; Child; Child, Preschool; Chlorambucil; Clinical Trials as Topic; Cyclophos	1974
A controlled prospective study of cyclophosphamide in relapsing, corticosteroid-responsive, minimal-lesion nephrotic syndrome in childhood. The Journal of pediatrics, 1973, Volume: 82, Issue:4 Topics: Adolescent; Alopecia; Child; Cyclophosphamide; Cystitis; Drug Synergism; Female; Humans; Hypercholes	1973
Controlled trial of prednisone in adult patients with the nephrotic syndrome. British medical journal, 1970, Aug-22, Volume: 3, Issue:5720 Topics: Adolescent; Adult; Aged; Biopsy; Cardiovascular Diseases; Clinical Trials as Topic; Female; Glomerul	1970
Controlled trial of azathioprine and prednisone in chronic renal disease. Report by Medical Research Council Working Party. British medical journal, 1971, May-01, Volume: 2, Issue:5756 Topics: Adolescent; Adult; Age Factors; Azathioprine; Child; Chronic Disease; Clinical Trials as Topic; Crea	1971
Paired trial of cyclophosphamide and prednisone in children with nephrosis. Archives of disease in childhood, 1971, Volume: 46, Issue:247 Topics: Child; Child, Preschool; Clinical Trials as Topic; Cyclophosphamide; Diuresis; Female; Humans; Kidne	1971
Modification by drugs of urinary fibrin/fibrinogen degradation products in glomerulonephritis. British medical journal, 1972, Jul-29, Volume: 3, Issue:5821 Topics: Adolescent; Adult; Aged; Aspirin; Child; Creatinine; Female; Fibrin; Fibrinogen; Glomerulonephritis;	1972

prednisone and Proteinuria